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Kurzfassung 
Zelluläre Seneszenz ist ein Zustand, der durch irreversiblen Proliferationsarrest 
charakterisiert ist, durch unterschiedliche Arten von intrinsischem und extrinsischem Stress 
ausgelöst werden kann und des Weiteren mit Tumorsuppression assoziiert ist. Seneszente 
Zellen bleiben metabolisch aktiv und sezernieren viele Faktoren. Dazu gehören 
Wachstumsfaktoren und Zytokine, welche die umgebenden Zellen beeinflussen und deren 
Zellwachstum fördern können. 
Das Neuroblastom (NB) ist ein Tumor des vegetativen Nervensystems und der häufigste 
extrakraniale solide Tumor im Kindesalter. Die Amplifikation des MYCN Onkogens ist 
charakteristisch für aggressive Formen des Neuroblastoms und ein hoch-signifikanter Marker 
für eine schlechte Prognose. Kürzlich wurde gezeigt, dass in MYCN amplifizierten NB-Zellen, 
die aus Primärtumoren von Stadium 3 oder 4 Patienten stammen, durch 6-8 wöchige 
Behandlung mit Hydroxyurea in vitro Seneszenz induziert werden kann. Nach Behandlung 
mit Hydroxyurea reduzieren seneszente NB-Zellen ihre MYCN Kopien Zahl und den NB-
Tumormarker GD2, während die Oberflächenmoleküle CD44 und MHC Klasse I 
hochreguliert werden. 
Das Immunsystem spielt eine wesentliche Rolle in der Vernichtung von Tumorzellen und 
durch die Produktion von inflammatorischen Faktoren beeinflusst es auch den 
Krankheitsverlauf. Zytotoxische T-Lymphozyten, natürliche Killerzellen und T-Helferzellen 
tragen signifikant zur Eradikation von Tumorzellen bei. Es wurde von anderen 
Arbeitsgruppen gezeigt, dass NB-Zellen nur gering immunogen sind und daher dem 
Immunsystem ausweichen können. Die Rolle dieser Immunzellen in Therapie-induzierter 
Seneszenz beim Neuroblastom ist nicht bekannt. 
Unser Ziel war es zu analysieren, ob Seneszenz in MYCN amplifizierten NB-Zellen durch 
andere Medikamente, z.B. Camptothecin und Bromdesoxyuridin, in vitro schneller induziert 
werden kann als durch Behandlung mit Hydroxyurea und wie diese Medikamente im 
Vergleich zu den unbehandelten Kontrollzellen das Wachstumsverhalten, die Proliferation, 
MYCN Kopien Zahl, den GD2 Gehalt und die CD44 und MHC Klasse I Tumormarker 
Expression verändern. Um zu analysieren, welche molekularen Wege der Seneszenz 
Induktion durch Behandlung mit den verschiedenen Medikamenten zugrunde liegen, haben 
wir die p16, p53 und CDK2 Expression mittels Western Blot bestimmt. Weiters haben wir in 
einer Co-Kultur erforscht, ob seneszente NB-Zellen die Proliferation und die Tumormarker 
Expression von nicht-seneszenten Zellen in der Umgebung beeinflussen. Darüber hinaus 
haben wir auch Co-Kulturen mit nicht-seneszenten bzw. seneszenten NB-Zellen und T-
Zellen angesetzt, um herauszufinden, ob seneszente NB-Zellen die Proliferation von T-Zellen 
erlauben. 
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Wir konnten zeigen, dass Camptothecin und Bromdesoxyuridin Behandlung schon nach 3 
Wochen zu Seneszenz in MYCN amplifizierten NB-Zellen in vitro geführt hat. Dies konnte 
durch Untersuchung der Morphologie, SA-β-Gal Färbung, Reduktion der MYCN Kopien Zahl 
und des GD2 Levels und einer Hochregulierung von CD44 und MHC I gezeigt werden. Diese 
Eigenschaften waren ähnlich wie bei den spontan seneszenten und Hydroxyurea 
behandelten seneszenten NB-Zellen. Weiterhin weisen unsere Daten, im Hinblick auf CD8+ 
und CD4+ T-Zellen, auf eine immunstimulierende Rolle der seneszenten NB Tumorzellen hin. 
Die Induktion von Seneszenz in MYCN amplifizierten NB-Zellen, durch Behandlung mit 
Medikamenten in geringen Konzentrationen, zeigt Potential im Hinblick auf Einschränkung 
des Tumorwachstums, Inhibierung des aggressiven Phänotyps in NB-Zellen und Erhöhung 
der Immunogenität von NB Tumorzellen. Diese Eigenschaften, die durch die Seneszenz 
Induktion ausgelöst werden, könnten in der klinischen Anwendung wichtig sein, um ein 
Tumorrezidiv in NB Patienten zu verhindern. 
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Abstract 
Cellular senescence, a state of permanent cell-cycle arrest, can be triggered by various types 
of intrinsic and extrinsic stress and is associated with tumour suppression. However, 
senescent cells remain metabolically active and produce many secreted factors, such as 
growth factors and cytokines, which affect nearby cells and may also promote their 
proliferation. Neuroblastoma (NB) is a tumour derived from cells of the sympathetic nervous 
system and comprises the most common extra cranial solid tumour of childhood.  
Amplification of the MYCN oncogene characterizes aggressive NBs and is a prediction 
marker for poor outcome. Recently, it was shown that in vitro 6-8 weeks hydroxyurea 
treatment is a potent senescence inducing application in MYCN amplified neuroblastoma cell 
lines, derived from the primary tumour of stage 3 or 4 patients. Senescent NB-cells decrease 
MYCN copy number and the NB tumour marker GD2, while the surface molecules CD44 and 
MHC class I are upregulated upon hydroxyurea treatment. The immune system plays an 
important part in eradication of tumour cells, but also by producing inflammatory signals and 
thus influencing disease progression. Cytotoxic T-lymphocytes, Natural killer cells and CD4+ 
T-cells significantly contribute to tumour cell erradication. It has been shown, that NB-cells 
are low immunogenic and therefore evade the immune system. The role of these immune 
cells in therapy-induced senescence in neuroblastoma is not known.  
We aimed to analyze, whether senescene in MYCN amplified NB-cells can be induced faster 
than with hydroxyurea by using drugs such as camptothecin and bromodeoxyuridine and how 
those drugs change the growth behaviour, proliferation, MYCN copy number, GD2 level and 
tumour marker expression CD44 and MHC class I compared to control cells. In order to 
analyse the underlying cellular pathways leading to senescence by these different drug 
treatments we have evaluated p16, p53 and CDK2 by western blot. Furthermore, we studied 
whether senescent NB-cells modulate proliferation and tumour marker expression of nearby 
non-senescent cells in co-culture. Additionally, we co-cultured T-cells with non-senescent 
and senescent NB-cells to see whether senescent NB-cells allow T-cell proliferation. 
We could show, that camptothecin and bromodeoxyuridine treatment induced senescence 
already after 3 weeks in MYCN amplified NB-cells in vitro, proved by morphology, SA-β-Gal 
staining, MYCN copy number reduction, GD2 level decrease and CD44 and MHC I 
upregulation which was similar to spontaneous senescent and hydroxyurea treated 
senescent NB-cells. Moreover, our data suggest an immune-stimulatory role of senescent 
tumour cells with respect to CD8+ and CD4+ T-cells.  
Inducing senescence in MYCN amplified neuroblastoma cells by low-dose drug-treatment in 
vitro has the potential to restrict tumour growth, inhibit the aggressive phenotype in NB-cells 
and render tumour cells immunogenic. These features of senescence induction could be 
important in clinical applications to prevent tumour relapse in NB patients. 
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1 Introduction 
1.1 Neuroblastoma 
Neuroblastoma (NB) is an embryonal tumour of the sympathetic nervous system that derives 
from multi-potent neural crest cells. It accounts for 7–10% of all childhood cancers, and it is 
the most common extra cranial solid tumour of childhood [1]. The disease is diagnosed at the 
median age of about 18 months. 40% are diagnosed by one year, 75% by four years and 
98% by 10 years of age. The cause of neuroblastoma is unknown, but it seems unlikely that 
environment plays a significant role [2]. Neuroblastoma is a disease of the 
sympathicoadrenal lineage of the neural crest. For this reason tumours can arise anywhere 
within the sympathetic nervous system. Most tumours develop within the abdomen and more 
than half of these are located in the adrenal medulla. Other common sites of tumour 
appearance are the neck, the chest and the pelvis. Depending on the site of the primary 
tumour, the metastases and the involved metabolic changes, the disease shows a wide 
diversity of signs and symptoms [3]. 
The various stages of neuronal differentiation of tumour cells show some prognostic 
significance. Most neuroblastomas are poorly differentiated and consist of small, round cells 
with scant cytoplasm called neuroblasts, which represent either immaturity or 
aggressiveness. However some tumours, the ganglioneuroblastomas, show histological 
differentiation. They are characterized by a mixture of mature or maturing ganglion cells and 
neuroblasts without neural differentiation. In the most differentiated and benign type of 
tumours, the ganglioneuroma, clusters of mature neurons surrounded by a dense stroma of 
Schwann cells are found [4-6]. 
The clinical hallmark of neuroblastoma is heterogeneity, meaning the tumour has a diverse 
spectrum of clinical presentation, prognosis and genomic features. Some tumours show 
spontaneous regression, particularly in infants, or they differentiate into a benign 
ganglioneuroma even without therapy [7]. Others display a very malignant phenotype that is 
poorly responsive to current intensive therapies and metastasize in advanced stages, mostly 
in children of more than one year of age [5]. According to age at diagnosis, the stage of 
disease and tumour biology the likeliness of tumour progression and survival varies broadly 
[8, 9]. Correlations between clinical outcome and some genetic features, such as oncogene 
amplification, DNA-content (ploidy status) or allelic loss have been identified. For instance, 
one marker for favourable clinical outcome and good survival rates is near-triploidy [10]. 55% 
of primary neuroblastomas are triploid or near-triploid, meaning they have between 58 and 
80 chromosomes [11]. These tumours have almost always whole chromosome gains and 
only in rare cases structural rearrangements [12]. Furthermore, benign types of tumours 
usually have a high expression of neurotrophin receptor TrkA, which probably mediates 
apoptosis or differentiation in neuroblastoma. Patients with this kind of neuroblastomas are 
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usually younger than one year of age, more likely have localized tumours and altogether 
have a good prognosis. In contrast unfavourable tumours are mostly near-diploid (35-57 
chromosomes) or near-tetraploid (81-103 chromosomes) [11] and are characterized by 
deletions of 1p36 (in 30% of NB) or 11q23 (in 40% of NB)  [13-16], an unbalanced gain of 
17q21 [17-19] and amplification of the oncogene MYCN [12, 20, 21]. Contrary to TrkA, a high 
TrkB expression together with its ligand brain-derived neurotrophic factor (BDNF) may lead 
to a survival pathway in aggressive tumours, especially in MYCN amplified (MNA) tumours. 
These patients are more likely older than one year and they have a poor prognosis. Further 
studies have shown that also deletions on chromosome 3p, 4p, 9p and 12p have prognostic 
significance [22-24].  
In 1986 the International Neuroblastoma Staging System (INSS) was proposed (and revised 
in 1993) classifying neuroblastoma according to its anatomical presence at diagnosis [25]. 
Since then most cancer centres have used the INSS to stage neuroblastoma. The stages are 
described in table 1. 
 
Stage  Description 
1 The tumour is in only one area and all the tumour that can be seen is completely removed during surgery 
2A The tumour is in only one area and all the tumour that can be seen cannot be completely removed during surgery 
2B 
The tumour is in only one area and all tumours that can be seen may be 
completely removed during surgery. Cancer cells are found in the lymph nodes 
near the tumour. 
3 
The tumour cannot be completely removed during surgery and has spread from 
one side of the body to the other side and may also have spread to nearby 
lymph nodes; or the tumour is in only one area, on one side of the body, but has 
spread to lymph nodes on the other side of the body; or the tumour is in the 
middle of the body and has spread to tissues or lymph nodes on both sides of 
the body, and the tumour cannot be removed by surgery. 
4 The tumour has spread to distant lymph nodes, the skin, or other parts of the body 
4-S 
The child is younger than 1 year and the cancer has spread to the skin, liver 
and/or bone marrow; and the tumour is in only one area and all of the tumour 
that can be seen may be completely removed during surgery, and/or cancer 
cells may be found in the lymph nodes near the tumour 
 
Table 1│ The International Neuroblastoma Staging System (content is taken from the website of the 
National Cancer Institute) 
 
Next to the stage of neuroblastoma, several other factors also affect prognosis, including the 
age of the child, tumour histology, tumour cell ploidy, cytogenetic abnormalities and MYCN 
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gene status. These factors are used to determine the risk group of neuroblastoma patients. 
Due to the heterogenous behaviour of the tumour patients are categorized into a low-, 
intermediate- or high-risk group [26] to predict the outcome of therapy and select appropriate 
patient treatment strategies. Patients with low-risk neuroblastoma are mostly cured through 
surgery without treatment [27] whereas patients with intermediate-risk are treated with 
surgery and chemotherapy [28]. For high-risk patients there are several therapies including 
surgery, radiation therapy, chemotherapy, bone marrow or haematopoietic stem cell (HSC) 
transplantation. Following HSC-transplantation high-risk neuroblastoma patients are 
frequently treated with 13-cis-retinoic acid and immunotherapy with monoclonal antibodies 
targeting GD2, which is the predominant tumour-specific antigen in NB-cells, and/or 
cytokines (GM-CSF or IL-2) [27-30]. Despite these therapies, a lot of patients, particularly 
with high-risk neuroblastoma,  suffer relapse mostly in bone or bone marrow [28]. The 3-year 
survival ranges from 99%, for tumours with good prognosis, to only 30% for aggressive 
tumours [5].  
Although a subset of patients with neuroblastoma shows a predisposition to develop this 
disease, most neuroblastomas develop spontaneously through gain or loss of alleles, ploidy 
changes or amplification of oncogenes [5].  
 
1.1.1 Amplification of the MYCN proto-oncogene 
The overall incidence of MYCN amplification in neuroblastoma is about 22% [5] and 
amplification of this oncogene is linked to aggressiveness of the disease [21]. 40% of the 
patients with advanced disease and  only 5-10% of the patients with low stage disease have 
a MYCN amplification [20]. The MYCN gene like the c-MYC gene is a member of the MYC-
related oncogene family. It was first found in neuroblastoma cell lines as amplified DNA that 
shows a homology to viral myc [31, 32]. MYCN maps to the distal short arm of chromosome 
2. When amplified, it is mainly located on extrachromosomal double-minutes (dmin) or 
infrequently in intrachromosomal homogeneously staining regions (hsr) which are both 
manifestations of gene amplification [33, 34]. The amplified part can vary in size and 
comprises a large region from chromosome 2p24 including the MYCN locus. This region is 
excised to form an extrachromosomal circular element (dmin) [34]. Under selective pressure, 
hsrs are generated through integration of the amplified DNA back into the genome [35]. 
MYCN is the only gene from this region showing consistent amplification, but other genes 
can be co-amplified as well. Until now, three genes have been found to be frequently co-
amplified with MYCN in neuroblastomas: DDX1, N-cym and NAG. Moreover these genes 
frequently show an increased expression when co-amplified in NB-cell lines, assuming a 
contribution to the NB tumour phenotype [36-38]. In addition to neuroblastoma, MYCN 
amplification or overexpression exists also in several other cancers that are often of 
neuroendocrine or embryonic origin. These tumours are for instance retinoblastoma [39], 
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glioblastoma, Wilms´ tumour [40] and medulloblastoma [41]. It is still not completely 
understood why amplification of MYCN is associated with the aggressive type of 
neuroblastoma. However, MYCN amplification mostly correlates with MYCN overexpression 
on the protein level [42]. 
 
1.1.2 MYCN expression and function 
MYCN like the other MYC family proteins is a transcription factor that influences expression 
of many target genes and therefore controls important cellular processes like proliferation, 
apoptosis, differentiation, protein synthesis and metabolism [28]. MYC transcription factors 
have a conserved structure consisting of a transcriptional activation domain of the N-terminus 
and a C-terminus basic helix-loop-helix leucine zipper domain, which is important for 
dimerization, DNA binding and transcription regulation [43]. MYC proteins form a protein 
complex with their binding partner MAX. This MYC-MAX dimer acts as a transcriptional 
activator [44]. However, MYCN can also repress the expression of genes, for instance it 
regulates genes involved in cell adhesion. Despite many similar properties of c-MYC and 
MYCN proteins like dimerization with MAX and binding to DNA, they differ significantly in 
their pattern of expression in normal tissues. In adult human and mice, c-MYC expression is 
present in all proliferating tissues while MYCN expression is very low or even absent. MYCN 
expression is restricted only to certain tissues in the developing embryo [45-48], for instance 
there are high levels in the neuroepithelium. In contrast to that c-myc is expressed in many 
tissues but is almost absent in this highly proliferative tissue. MCYN is also found in the 
developing intestine, kidney, heart and lung [46, 49]. Despite expression pattern differences, 
MCYN can functionally replace c-MYC in murine development [50]. In Th-MYCN transgenic 
mice, an animal model for neuroblastoma in which the MYCN expression is under the control 
of the tyrosine hydroxylase promoter, MYCN has been shown to promote proliferation and 
prevent differentiation of neuronal progenitors during embryonic development leading to the 
formation of hyperplastic lesions [51]. This study suggests that MYCN expression has to be 
down-regulated in order to allow differentiation into mature neurons. 
 
 
1.2 Senescence 
1.2.1 General features and biomarkers 
Cells that are exposed to stress, respond either by apoptosis, by transient growth arrest or by 
entry into senescence. The cell fate is dependent on the cell type and the kind and level of 
stress. Senescence was first described by Hayflick and Moorhead (1961) in normal human 
fibroblasts in vitro. It was defined as the state of irreversible long-term cell cycle arrest that 
cells enter when they reach the end of their replicative lifespan [52]. This arrest in the G1/G0 
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phase of the cell cycle is an indispensable marker for identifying all types of cellular 
senescence in vitro as well as in vivo [53]. Germline, cancer and certain stem cells possess 
in contrast an indefinite replicative capacity [54].  
Further, senescent cells lose the ability to respond to growth factors [55] and they undergo a 
dramatic change in morphology. Senescent cells alter their original shape and, depending on 
the trigger, they can increase their volume, acquire a flattened cytoplasm, become 
multinucleated and increase adhesion to the extracellular matrix while losing cell-cell 
contacts [56]. Cells that have undergone senescence almost stop to proliferate, but remain in 
a viable, metabolic active state for months in vitro [57]. In addition, many (but not all) cell 
types become resistant to certain apoptotic signals when they acquire senescence [58]. The 
underlying mechanisms are not completely understood, but expression changes in proteins 
that either inhibit or promote apoptosis might be a cause for resistance in some cells [59]. In 
other cell types, the tumour suppressor p53 is supposed to prefer transactivation of genes 
that arrest cell proliferation, rather than genes that lead to apoptosis [60]. 
A commonly used senescence biomarker is acidic senescence-associated β-galactosidase 
(SA-β-gal) [61], which has a highly increased activity in senescent cells. This happens 
presumably due to an expansion of the lysosomal compartment, which leads to an increase 
in SA-β-gal activity [62]. During senescence also the gene expression alters and therewith 
the secretome of senescent cells. Factors such as cytokines and chemokines are secreted, 
affecting the microenvironment and the surrounding cells [63, 64].  These profound changes 
in the secretome of cells entering the senescent stage are termed the senescence-
associated secretory phenotype (SASP) [65]. However, the gene expression changes 
occurring in senescent cells are specific and mostly conserved within individual cell types 
[66]. 
Gene expression changes can be explained in part through alterations in the structure of 
chromatin [63]. After treatment with a DNA binding dye senescent cells often display 
remarkable punctate staining regions different from the overall homogenous patterns of 
cycling human cells. These DNA regions are termed senescence-associated heterochromatic 
foci (SAHF), which are highly condensed chromatin regions that are proposed to enforce 
cellular senescence by silencing genes involved in proliferation. SAHF are notably enriched 
in trimethylated lysine 9 of histone H3 (H3K9), and associate with a group A protein and 
heterochromatin protein 1 [67-69]. However, not all cell types of senescent cells show 
SAHFs. Therefore the establishment of cellular senescence is not dependent on the 
formation of SAHFs. Moreover, not all stimuli leading to senescence in cells concomitantly 
induce SAHFs, e.g. in human skin fibroblasts SAHFs are preferentially formed after 
oncogene induced senescence, but not after telomere shortening, exposure to ionizing 
radiation, treatment with H2O2 or hydroxyurea [70]. 
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Hayflick and Moorhead (1961) suggested that the proliferation of normal cells is limited 
trough the loss of determined cellular factors during several cell divisions. Nowadays, cellular 
senescence is considered to be a response triggered by a combination of at least three 
mechanisms, which are telomere shortening, accumulation of DNA damage and 
derepression of the INK4a/ARF locus (Fig. 1). To which extent these mechanisms contribute 
to the senescence process depends on the cell type and the culture conditions [71].  
Oncogene activation in vivo often leads to cellular senescence suggesting that the 
senescence pathway may be as important as apoptosis for protection against cancer. 
Further, senescence has been linked to organismal aging [71-74].  
 
 
Figure 1│ Hayflick factors record the proliferative history of cells and tissues 
The three best-known Hayflick factors—telomere shortening, accumulation of DNA damage, and 
derepression of the INK4a/ARF locus—are summarized together with their main effectors, the tumour 
suppressors p53 and retinoblastoma (Rb) (taken from Collado et al, 2007 [71]) 
 
1.2.2 Theories of Senescence  
Senescence can be subdivided into “replicative senescence”, referring to a senescence 
process that occurs following extended proliferation, most likely triggered by a cell-intrinsic 
mechanism, and “stress-induced premature senescence”, referring to senescence triggered 
by extrinsic and intrinsic stress. 
 
1.2.2.1 Replicative Senescence 
During the process of cell proliferation telomeres are progressively shortened from one cell 
division to another, driving the cells to undergo replicative senescence when the telomeres 
reached a critical length. 
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1.2.2.1.1 Telomere shortening 
Telomeres, the ends of linear chromosomes, consist of repetitive DNA elements and protect 
DNA ends from degradation and recombination [75, 76]. Telomeres become gradually 
shorter with every cell division round, because the replication machinery is incapable to copy 
the ends of linear molecules. This phenomenon is called the end replication problem. The 
telomere length gives information about cell division and cell cycle arrest [77]. In the end, 
telomeres reach a critical short length and behave like double-stranded DNA breaks. 
Consequently, the tumour suppressor protein p53 is activated and either starts the telomere-
initiated senescence, also called replicative senescence, or cell apoptosis [76, 78]. 
Telomerase is a ribonucleoprotein with DNA polymerase activity and has the ability to 
elongate telomeres, thereby avoiding the effect of the end replication problem. In contrast to 
stem cells, telomerase is not expressed in human somatic cells. This fact makes most 
primary human cells unable to maintain their telomeres to inhibit a DNA damage response 
(DDR), which explains their limited life span [79]. In contrast, most human cancer cells 
possess the ability to maintain or elongate their telomeres, basically through a high 
telomerase expression [80] or a mechanism termed alternative lengthening of telomeres 
(ALT) [81].  This maintenance of telomere length permits cancer cells to proliferate 
indefinitely. 
It is a common practice to immortalize primary human cells in vitro through the ectopic 
expression of the catalytic subunit of the telomerase holoenzyme (hTERT), which elongates 
telomeres. Further, there are studies showing that mice deficient in telomerase activity are 
significantly resistant to cancer induced by genetic defects or carcinogenic treatment [77]. 
These facts underline that telomere shortening plays an important role in cellular senescence 
[82].  
 
1.2.2.2 Premature Senescence 
Cells that possess endogenous telomerase activity maintain their telomere length but still can 
acquire a senescent status. Thus, there must be other triggers able to shorten the intrinsic 
replicative lifespan of a cell and inducing a senescence phenotype. Cells can initiate the 
senescence program not only through replicative senescence, but also due to diverse 
stressors including oxidative stress, reactive oxygen species (ROS), inactivation of tumour 
suppressor genes or activation of oncogenes. This type of senescence is termed premature 
senescence, since the cell proliferation capacity is limited prior to the effect of telomere 
shortening. The distinction between replicative and premature senescence does not 
necessarily describe two independent cellular mechanisms, but the fact that different 
stresses can cause a common cellular response. 
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1.2.2.2.1 Senescence induced by extrinsic signals 
Cellular senescence can be triggered by extrinsic stress such as DNA-damaging treatments 
or agents (e.g. γ-irradiation, bleomycin or actinomycin D) [83, 84] or through oxidative stress 
(e.g. treatment with H2O2) [85, 86]. 
In cell culture, ionizing radiation does not induce apoptosis of human fibroblasts, but rather a 
senescence-like arrest [87]. Chemotherapeutic substances have been shown to induce cell 
cycle arrest and senescence in vitro, for instance treatment of human colon cancer cells with 
a low concentration of camptothecin or treatment of human erythroleukemia cells with 
hydroxyurea lead to senescence [88-90].  
These in vitro findings have been supported by several reports on senescent tumour cells in 
vivo. In everyday clinical treatment of human cancers, tumour cells are forced into 
senescence. Studies reported that cell lines derived from different human solid tumours show 
senescence-like morphological changes and SA-β gal expression after ionizing radiation and 
treatment with various chemotherapeutic substances [89]. 
 Even without drug treatment some of the tumour cell lines, which are said to be immortal, 
display the senescent phenotype in a significant minority of the cells (10–20%) [91]. This 
finding suggests that tumour cells could senesce spontaneously and that this process could 
occur in response to environmental changes of the cell [89]. In fact, inadequate culturing 
conditions in vitro can cause premature senescence. Cells have to acclimate to an artificial 
environment, when they are explanted and cultured. In vitro, other concentrations of nutrients 
and growth factors exist. Cells have to adapt to the absence of neighbouring cells and factors 
from the extracellular matrix. Further, cells are influenced by the oxygen levels surrounding 
them [92]. It is widely assumed that rather ROS than oxygen itself is involved in senescence. 
ROS are produced by mitochondria and ROS levels are elevated in senescent cells [93]. 
Each of the above mentioned conditions can induce a culture shock initiating stress-induced 
senescence independent of telomere length. 
 
1.2.2.2.2 Oncogene-induced senescence 
The concept of oncogene-induced senescence emerged with the study of Serrano et al. 
(1997), in which normal cells were forced to express high levels of an oncogenic version of 
HRAS, whereupon these cells entered the cell cycle arrest and changed their morphology 
indistinguishable from replicative senescent cells. This phenomenon is called oncogene-
induced senescence (OIS). In contrast to replicative senescence it cannot be prevented by 
the ectopic expression of hTERT, which elongates telomeres, confirming that OIS is 
independent from telomere shortening [94]. Two well-known tumour suppressors were shown 
to be up-regulated and to play an important role in leading those cells into the cell cycle 
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arrest. These factors are INK4A, which activates the RB family, and ARF, which activates 
p53 [95]. 
Moreover, OIS is for instance induced by aberrant activation of oncogenes like Ras, BRAF or 
Myc [96]. Although overexpression of oncogenes primarily induces apoptosis or senescence, 
certain oncogenes (e.g. Myc) can also suppress these processes. Myc even suppresses 
Ras-induced senescence. Hence Myc and Ras may neutralize their anti-tumourigenic 
activity, allowing the tumour to proliferate. Thus, not only activation but also inactivation of 
some oncogenes can result in senescence and tumour regression [97, 98]. 
 
1.2.2.2.3 Tumour suppressor loss-induced senescence  
Similarly to oncogene overexpression or mutation, shown for PTEN and NF1, the loss of a 
tumour suppressor in cells can also activate the senescence pathway. Mouse embryonic 
fibroblasts (MEFs) deficient for PTEN undergo senescence while p53 is concomitantly 
induced. Additional deletion of p53 allows the cell to bypass the effect of PTEN loss [99]. 
Likewise, NF1 depletion induces senescence in vitro and simultaneously there is a decrease 
in the activity of ERK and AKT [100].  
 
These different senescence triggers are not independent from one another. Extrinsic 
stresses may affect intrinsic factors e.g. oxidative stress may affect the accumulation of DNA 
damage and accelerate telomere shortening. A population of cells may suffer from multiple 
stressors, which can lead to a complex cumulative effect [101].  
 
1.2.3 Senescence Signalling Pathways 
A variety of stressors can initiate cells to adopt a senescent phenotype. This observation 
supports the theory that senescence is a general response mechanism, which is not 
restricted to a certain type of stress. Furthermore, a number of changes in morphology and 
function occur upon activation of senescence. These changes can be assigned to specific 
molecular pathways.  
 
In general, two pathways are responsible for the establishment and maintenance of growth 
arrest during senescence: the p53 and the retinoblastoma protein (pRb) pathway (Fig. 2).  
The INK4a/ARF locus encodes the proteins p16INK4a and p14ARF (p19ARF in mouse). Both 
proteins possess anti-proliferative activity and interact with the p53 and pRb tumour 
suppressor pathway, although they use different molecular effectors [102, 103]. p16INK4a 
inhibits the assembly of cyclin dependent kinase 4/6 (CDK4, CDK6) and cyclin D (CycD) and 
thus the activated complex, which otherwise would phosphorylate pRb and pRb-related 
proteins (p107 and p130). Without the phosphorylation of pRb and related proteins the 
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transcription of E2F target genes is inhibited. E2F is essential for the transition from G1 to S-
phase and mitosis. Hence, this process prevents the progression of the cell cycle, because 
p16INK4a maintains the active unphosphorylated state of pRb, which inhibits cell growth [102]. 
 
Figure 2│The molecular circuitry of senescence 
p53 and Rb are the main activators of senescence. p53 can activate senescence by activating Rb through 
p21 and other so far unknown proteins, and also, in human cells, can activate senescence independently of 
Rb. Rb activates senescence by shutting down the transcription of E2f target genes. Rb is activated either by 
p21 or by the p16INK4a product. p53 activation is achieved by phosphorylation, performed by the ATM/ATR 
and Chk1/Chk2 proteins, and by the p14/p19ARF product of the INK4a locus, which sequesters Mdm2 in the 
nucleolus. The transcriptional control of the INK4a products is not fully elucidated, indicated are some of 
these regulators (adapted from Ben-Porath et al, 2005 [101]). 
 
The other product of the INK4a/ARF locus, p14ARF, stabilizes p53 by binding to MDM2, which 
otherwise would target p53 for degradation. The tumour suppressor p53 can induce an 
important downstream factor, the cell cycle inhibitor p21CIP1, that blocks the phosphorylation 
of pRb by modulating CDK2/cyclin E complexes and thus initiate a cell cycle arrest. However, 
beside the induction of senescence, p53 activation can also cause apoptosis. The reason, 
why a cell decides for the one or the other way is not yet understood [102].  
The activation of p53 can also be induced through the DDR signalling cascade sensing and 
repairing DNA damage. It is activated through phosphatidylinositol 3-kinase-like protein 
kinases such as ATR and ATM. These kinases phosphorylate chromatin modifying proteins 
such as γH2AX, adapter proteins (NBS1), and further kinases such as CHK1 and CHK2, 
which are downstream in this pathway and in turn activate p53 by phosphorylation [104].  
Activation of p53 or p16INK4a or simultaneous activation of both pathways respectively, results 
in inhibition of pRb phosphorylation. So, p53 and p16INK4a can be seen as a processing unit 
transforming different incoming stress signals (e.g. telomere shortening, irradiation, DNA-
damaging agents, ROS) into a common adequate cellular response.  
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In addition, p38-MAPK proteins have been shown to be important in mediating senescence 
caused by oxidative stress and high levels of RAS. Activation of the p38MAPK/NF-κB 
pathway also plays an essential role in the induction of the SASP, which needs several days 
to develop after a DDR [102]. 
Taken together, the cyclin-dependent kinase inhibitors (CKIs) p16 and p21 are two critical 
senescence regulators. Their expression is elevated in most types of senescent cells and 
their function is to block the activity of Cdks, which in turn leads to an up-regulated Rb activity 
and thereby induces senescence [105].  
 
Additionally, the CKI p27 is also regarded as an important effector of cellular senescence 
which is part of a third pathway, the PTEN/p27Kip1 pathway (Fig. 3) [106]. Loss of the tumour 
suppressor PTEN occurs in a variety of human cancers. PTEN, a phosphatase, catalyses the 
conversion of PIP3 into PIP2. The proto-oncogene, PI3-kinase counteracts this action of 
PTEN. Overexpression of PTEN, as well as the effect of PI3K inhibitors result in up-
regulation of the CKI p27 [107], which occurs by protein stabilization in response to 
decreased PIP3 levels. 
Human fibroblasts treated with PI3K inhibitors accelerate the onset of cellular senescence 
and senescent human fibroblasts display an accumulation of p27 [108]. Further, p27 levels 
are often significantly diminished in human tumours especially in advanced stages [109]. 
 
 
Figure 3│The PTEN/p27Kip1 pathway (taken from Bringold, F. and M. Serrano, 2000 [106]) 
 
1.2.4 Senescence as a barrier to tumorigenesis 
Senescent tumour cells were identified in pre-malignant stages of tumours (e.g. in lung 
adenomas and melanocytic nevi), but in their corresponding malignant stages senescence 
was absent. This observation suggests a role for senescence as a barrier to tumour 
progression [110]. When a normal cell acquires mutations in several cancer-causing genes, it 
can become malignant. Nowadays, senescence is anticipated to play an important role in the 
tumour suppression process in at least three ways. First, the tumour growth is stopped by 
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senescence associated proliferation arrest. Second, this proliferation arrest provides genetic 
stability by suppressing accumulation of additional oncogenic alterations during replication 
and mitosis. Third, senescent cells alert the immune system by secreting immune regulators 
to clear incipient cancer cells (Fig. 4) [111].  
 
 
Figure 4│Senescence as a tumour suppressor mechanism 
Acquisition of an activated oncogene or inactivation of a tumour suppressor initially causes a proliferative 
burst. Ultimately, senescence kicks in to arrest proliferation of the cells harbouring the oncogenic event. 
Proliferation arrest is reinforced through the secretome. Senescence-associated proliferation arrest is likely 
to arrest tumour progression by preventing proliferation of neoplastic cells and suppressing accumulation of 
additional genetic alterations (genome stability). In addition, senescence recruits the innate immune system 
to clear the genetically altered cells that threaten the host with malignant disease (taken from Adams, P.D., 
2009 [111]). 
 
In order to reach the potential to divide unlimitedly and to be able to transform into tumours, 
cells have to escape senescence. This step is one of the hallmarks of cancer cells [112]. In 
line with the aspect that the mechanism of senescence acts as a tumour suppressor, well-
known tumour suppressors as p53, p16, pRb, p21 and Arf are also regulators of senescence 
[112-114]. Deletion of some senescence regulators such as p53, Arf, p16 and p27 causes 
progression of tumours to a malignant stage [115, 116]. So, there is a causal link between 
malignant transformation and the loss of mediators of senescence. 
 
1.2.5 Senescence and aging 
Cellular senescence, although preventing initial stages of cancer, is also involved in 
organismal aging and even promotes the degenerative and cancerous pathologies of aging. 
Looking at physiological aging, an increase of molecular senescence biomarkers, such as 
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DNA damage, SA-β-gal, expression of p16INK4a and telomere shortening has been reported 
in some aging tissues [61, 117]. In addition, studies have shown increased levels of 
senescent cells in tissues of age-associated pathologies, such as osteoarthritis, 
atherosclerosis and liver cirrhosis [118-120]. 
  
 
Figure 5│Senescence of stem cells and committed cells 
Multiple mechanisms operate on stem cells and on committed cells to produce senescence. Telomere 
shortening, derepression of the INK4a/ARF locus, and the accumulation of DNA damage operate during the 
lifespan of the organism on stem cells (left side, from top to bottom), as well as on committed cells derived 
from the stem cells on their way to generating a differentiated tissue (from left to right). The final result is 
age-dependent loss of stem cell functionality (represented by a thin arrow in the top right) and an age-
dependent increase in the number of senescent cells in differentiated tissues (represented as blue cells). 
Tumours may arise at any point in life, but the stress signals characteristic of tumours will engage the 
senescence program. This tumour-specific senescence constitutes an important barrier to tumour 
progression (taken from Collado et al, 2007 [71]. 
 
There are two mechanisms that explain how cellular senescence may probably contribute to 
aging: accumulation of senescent cells in tissues during the aging process and loss of stem 
cell function by limiting the regenerative potential of stem cells (Fig. 5) [71]. As a result, these 
two factors could lead to impaired tissue homeostasis and function and consequently to 
aging of the organism.  
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1.2.6 Senescence in anticancer therapy 
Current anti-tumour chemotherapeutics are designed to kill cancer cells. The problem is that 
these therapies are often limited by pro-survival alterations present in cancer cells and that 
they are also toxic to normal cells. By attacking cancer cells from a different angle 
senescence-inducing drugs might offer an opportunity to reduce the toxicity of chemotherapy 
in healthy tissue. 
As aforementioned, senescence can be induced by DNA damage. This suggests that DNA 
damaging chemotherapeutic drugs may activate the senescence mechanism in tumour cells 
and in this way could contribute to the success of cancer treatment [83, 84, 121]. Studies in 
human breast cancer patients show positive staining for senescence markers in a high 
percentage of tumours. Furthermore, senescence induction in these tumours is associated 
with p53 and p16 activation. There was no induction of senescence in tumours before 
chemotherapy, which indicates that senescent cells are formed as a response to 
chemotherapy [122]. Likewise, chemotherapy induced senescence was found in biopsies 
from patients with lung and prostate cancer [65, 123]. For the reduction of tumour growth 
drugs inducing senescence might prove effective either alone or in a therapy combined with 
classic therapeutic approaches. 
In vitro, several human cancer cell lines undergo the senescence process when treated with 
moderate doses of classical chemotherapeutic drugs, but go into apoptosis when treated with 
higher doses [124, 125]. Cellular senescence as an end point of tumour therapy might be 
important for the development of new drugs for therapeutic treatments or as prognostic 
markers, respectively [110]. 
 
 
1.3 Senescence in MYCN amplified neuroblastoma cell lines  
In cultures of MYCN amplified primary neuroblastoma cell lines, senescent cells arise 
spontaneously at varying frequencies [125]. These cells are morphologically distinct from the 
majority of neuronal-type cells (N-cells): Senescent NB-cells show typical morphological 
characteristics of senescent cells, such as enlarged cytoplasm. Further they stop proliferation 
and show strong adherence to plastic surfaces. Due to their spontaneous appearance and 
their morphology these cells were named spontaneous flat (F)-cells [126].  
In contrast, N-type cells are small, light-refractile cells with neuronal features. Many N-cells 
possess usually short, thin processes, but some of them have also long processes searching 
connection to cells over a longer distance. They grow densely and form focal accumulations. 
Although morphologically different, both cell types share the same tumour-specific genetic 
aberrations, such as 1p loss or 17q gain [125, 127, 128]. However, they differ in the MYCN 
copy number status. Only 2-12% MYCN amplified cells were found in the F-cell population, 
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compared to 95% MYCN amplified cells in N-cells [126]. The reduced MYCN copy number is 
probably a result of micronucleus formation and expulsion of MYCN copies from the nucleus 
into the cytoplasm, where DNA is degraded in the lysosomal compartment. This mechanism 
has been suggested to contribute to senescence-onset in NB-cells [126]. 
 
1.3.1 Drug-induced senescence by hydroxyurea treatment in vitro 
Hydroxyurea (HU) is an “old” drug and used to treat patients with melanoma, chronic 
myelocytic leukaemia and metastatic cancer of the ovaries. HU is also given in combination 
with radiation treatment for head and neck cancer. Further, it is given to patients with sickle-
cell anaemia to prevent them from crisis. 
 
Studies have shown that treatment with low concentrations of hydroxyurea (HU) accelerates 
the expulsion of amplified genes in several tumour cell lines [129, 130]. Previous data have 
shown that low dose treatment with HU in MYCN amplified neuroblastoma cells result in an 
accelerated entrance into the senescence pathway. After 6-10 weeks HU induction the 
number of cells decreased and mostly only senescent cells remained in cell culture. More 
than 95% of cells stained positive for SA-β-Gal, the most accepted senescence marker. 3-4 
weeks after treatment start proliferation state dropped to 25% according to 
bromodeoxyuridine uptake and enlarged flat cells, F-cells, with increased granularity 
developed. After 5-8 weeks of treatment only cells having strongly reduced MYCN copy 
number were present in the culture. For some the number even went down to one copy per 
cell. Concurrently, CD44 and MHCI were up-regulated on the surface of HU-treated NB-cells. 
Moreover, telomeres were shorter and telomerase activity could not be detected after 8 
weeks of HU induction. Thus, HU induced senescent F-cells and spontaneous senescent F-
cells show similar features, such as up-regulation of CD44, MHCI and SA-β-Gal positivity 
[125]. 
Therefore, previous studies of our research group show that in the most aggressive MNA 
neuroblastomas the formation of senescent F-cells can be induced via low dose HU 
treatment within 6-10 weeks, which results in loss of their malignant properties [125]. 
 
1.3.2 GD2 level and CD44 expression  
The tumour-associated antigen disialoganglioside GD2 is present in high density on the 
surface of NB-cells [131]. In normal human tissues, expression of GD2 is restricted to 
neurons, peripheral sensory nerve fibres and skin melanocytes [132]. Thus, GD2 is a useful 
target for identification and treatment of tumour cells with monoclonal antibodies. We have 
previously found, that in NB primary cell lines N-cells express GD2, whereas senescent F-
cells are GD2 negative [125, 126].  
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The transmembrane glycoprotein CD44 is involved in cell-cell interactions and attachment to 
extracellular matrix mainly through hyaluronic acid. It has many isoforms generated through 
alternative splicing or alterations in glycosylation [133]. Expression of CD44 can be regulated 
by differentiation or mitogenic factors [134]. In malignancies of the hematopoietic system, 
CD44 variant expression in general is an unfavourable prognostic factor and is associated 
with tumour progression and dissemination [135]. Similar observations were made in breast 
and colon carcinomas [136, 137]. In contrast, CD44 expression in NB is related to low risk 
stages, differentiated NB tumours, with a favourable prognosis, while tumours negative for 
CD44 are progressive and metastatic with poor prognosis [138]. Furthermore, there is a 
strong relationship between the lack of CD44 expression and amplification of MYCN in NB 
[139]. In general, NB-cell lines do not express CD44 as they are mostly derived from 
aggressively growing high risk NB. In primary NB-cell lines derived from stage 3+4 patients 
we have previously reported that N-cells are CD44 negative, whereas senescent F-cells 
show a high expression of CD44 [125]. Upon treatment with HU we have observed that the 
number of CD44 positive cells increases and that these cells show different stages of 
micronuclei formation with packed MYCN signals or already reduced MYCN copies after 
expulsion. Cells that have expulsed supernumerary copies of MYCN also express MHC class 
I [125, 126]. This molecule is usually almost absent in neuroblastoma cells [140]. 
 
 
1.4 Immune evasion and antitumoural immune response against 
neuroblastoma 
The immune system not only detects and eliminates pathogens that may do harm to the 
organism, but also serves as a guardian against transformed cells that may lead to cancer.   
Most tumours are poorly immunogenic and consequently evade immune recognition and 
elimination. This is also a problem in aggressive neuroblastoma [141]. NB tumours have 
evolved several different ways to avoid or suppress an immune response, especially by 
targeting pathways required for the initiation of a successful T-cell, dendritic cell- and/or NK-
mediated tumour-specific immune response. Critical pathways that can be affected are: 
antigen processing and presentation via the MHC class molecules of proteins, TLR-mediated 
activation of antigen presenting cells, expression of ligands for activating NK 
immunoreceptors, and expression of co-stimulatory molecules and cytokines. In general, 
processing and presentation of tumour antigens by MHC class I molecules requires antigen 
degradation by the immuneproteasome. The resulting peptides are translocated into the 
lumen of the endoplasmatic reticulum by the TAP transporter assisted by chaperons. The 
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peptide is then loaded onto mature MHC class I molecules and subsequently transferred to 
the cell surface[142].  
NB-cell lines and primary tumours display low or absent expression of MHC class I and II 
molecules and defects in in β2-microglobulin (β2m), a subunit of MHC I [143, 144]. Primary 
NB tumours lack or show reduced expression of components of the immuneproteasome 
complex (PSMB10) and of the translocation machinery (tapasin (TAPBP), TAP1 or TAP2). 
These defects explain reduced peptide loading on MHC class I molecules, their instability 
and failure to be expressed on the cell surface [145] and therewith to a restricted or no 
recognition by CTL which mediate antigen-specific cytotoxic functions following peptide 
recognition on  MHC class I molecules [146].  
Another immuno-suppressive mechanism of NB-cells is shedding of gangliosides, such as 
GD2. Gangliosides are cell-membrane associated glycosphingolipids and are over-
expressed frequently in tumour cells. They are shed into the local microenvironment and 
plasma of tumour-bearing patients and inhibit antigen-processing and presentation, 
lymphocyte proliferation, Th-cell differentiation and activation of mast cells as well as 
differentiation and activation of antigen presenting cells (DC and monocytes) [147-155]. 
Furthermore, neuroblastoma cells potentially evade the immune system by releasing 
immunosupressive molecules, such as IL-10 and TGFβ, which prevents activation and 
expansion of tumour-infiltrating lymphocytes [156]. Finally, costimulatory molecules such as 
CD40, CD80, CD86 and others are down-regulated in NB-cell lines and primary NB tumours. 
The absence of CD40 in primary neuroblasts indicates that NB-cells may evade the 
programmed cell death mediated by CD40/CD40L interaction [157]. 
 
There are still a lot of questions in the field of immune response against NB-cells. It has been 
suggested that NK cells may target NB-cells much better than CTL, because of their low 
MHC class I expression [158, 159]. Indirectly, also NKT cells may mediate cytotoxicity 
against NB-cells by secreting IL-2, which activates NK cells [160]. Furthermore, the potential 
role of B-cells in NB progression is not yet clear and T regulatory cells (Tregs), positive for 
CD4, CD25 and Foxp3, have not been evaluated in NB tumours [161]. 
 
Attempts have been made to enhance immunogenicity in NB and to induce a tumour cell-
specific immune response in patients by immunotherapy [162, 163]. However, the only 
proven beneficial immunotherapy for NB high-risk patients is a chimeric anti-GD2 mAb 
(ch14.18) alone or combined with IL-2 or GM-CSF. It is given to patients after they have 
received intensive chemotherapy, irradiation, and surgery [164].  Other anti-neuroblastoma T 
cell therapy trials, such as vaccines and adoptive cell therapy, are still in early development 
and not yet proven to be successful. 
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The role of the immune system in mediating anti-tumour responses upon drug-induced 
oncogene inactivation and concomitant senescence in neuroblastoma is not known. 
Recently, it was reported by our group that MHC I surface expression is up-regulated on 
neuroblastoma cell lines by long-term (>8 weeks) low dose hydroxyurea treatment in vitro 
[125]. This finding and our preliminary studies suggest that hydroxyurea treated 
neuroblastoma cells allow CD8+ and CD4+ T-cell activation. Similarly, Rakhra K et al. have 
reported that in c-MYC-dependent tumours CD4+ T-cells are required for tumour regression 
upon oncogene inactivation in mice [165]. Also cells of the innate immune system have been 
implicated in senescence induction in malignant B-cell lymphoma via a strongly increased 
secretion of various cytokines, among them TGFβ [166]. Moreover, a study on liver cancer 
showed that mice with an impaired immune surveillance of senescent hepatocytes developed 
cancer, while in mice with normal active Th-cells senescent cells were removed before 
cancer could develop [167].  
 
Strategies to overcome the immunosuppressive behaviour of NB tumour cells and therewith 
enhance the anti-tumour immunotherapy still have to be developed. Thus our research 
focuses on inducing senescence in NB-cells derived from high risk patients by drug treatment 
and to study the resulting immunogenic changes of these senescent cells. 
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2 Materials and Methods 
2.1 Cell Culture 
All cell culture work was performed under sterile conditions. Cells were analysed with an 
Axiovert 40C inverted microscope (Zeiss, Austria) and photographed with PixeLINK software 
(Ottawa, USA). 
The two Neuroblastoma cell lines STA-NB-10 and NB-Ma were cultured in RPMI 1640 
GlutaMAX (Gibco-BRL, Grand Island, New York, USA) supplemented with 10% fetal calf 
serum (FCS Gold, PAA Laboratories GmbH, Pasching, Austria), 2,5% HEPES (PAA 
Laboratories GmbH), 1% Sodium-Pyruvate (PAA Laboratories GmbH) and 0,8% Penicillin 
(10.000 U/ml)/Streptomycin (10 mg/ml) (PAA Laboratories GmbH). Cultivation took place at 
37°C supplied with 5% CO2 and 90% relative humidity in an incubator. Cell passaging was 
done when cells were 80-90% confluent (on average once a week).  
To harvest the cells, they were washed first with phosphate-buffered saline (PBS, PAA 
Laboratories GmbH) and then incubated with 1.5 ml of Accutase (PAA Laboratories GmbH) 
at 37°C for 3-5min (for control cells) or 15-20 minutes (for spontaneous and induced 
senescent cells). Detached cells were resuspended in medium and either splitted into a new 
flask or used for experiments.  
To receive pure cultures of spontaneous senescent cells, N-cells were detached via 
Accutase treatment for 3-5 min and removed from the flask, thereby leaving only 
spontaneous senescent cells which could be further cultivated. 
 
2.1.1 Treatment with Hydroxyurea, Bromodeoxyuridine and Camptothecin  
Subconfluent cultures of STA-NB-10 and NB-Ma cells were treated either with 150 µM 
Hydroxyurea (Sigma-Aldrich, Austria) for 8-10 weeks or 20 µM Bromodeoxyuridine (Sigma-
Aldrich, Austria) or 5 nM Camptothecin (Sigma-Aldrich, Austria) for 3-5 weeks. Medium was 
renewed and drugs were added once a week. Medium of control cells was changed weekly 
and cells were passaged if necessary.  
 
2.1.2 Cell Counting 
Cells were counted with the Bürker-Türk counting chamber. Detached cells were 
resuspended in a definite volume of PBS or medium. 10 µl of cell suspension was mixed with 
10µl of Trypan blue to distinguish viable and non-viable cells (non-viable cells are stained 
blue). 10 µl of this suspension was pipetted into the Bürker-Türk counting chamber and 
viable cells were counted in each of the four corner squares.  
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Viable cell concentration was calculated using the formula: cells/ml = t x tb x 1/4 x 104 
 
 t = total viable cell count of four corner squares 
 tb = correction for the trypan blue dilution (counting dilution was 1/tb) 
 1/4 = correction to give mean cells per corner square 
 104 = conversion factor for counting chamber 
 
2.1.3 Co-culture of Hydroxyurea induced senescent cells and control cells 
HU induced senescent cells were detached via Accutase treatment (described in chapter 2.1) 
and total cell number was calculated after counting cells in a Bürker-Türk counting chamber 
(described in chapter 2.1.2). Cells were washed with PBS, resuspended in PBS and Cell 
Proliferation Dye eFluor670 (CPD, eBioscience, Austria) was added (1µl per 1x107 cells/ml). 
Incubation took place at 37°C for 10 min in an incubator. 5 ml FCS were added and 
incubated for 5 min at RT to stop the reaction. Cells were washed two times with PBS, 
resuspended in medium, transferred back to a culture flask and incubated for two days at 
37°C in an incubator. At the experimental day (day 0) CPD labelled HU induced senescent 
cells and control cells were harvested, counted and resuspended in medium (5x105 cells/ml). 
If necessary, wells were coated with fibronectin (Roche Diagnostics GmbH, Mannheim, 
Germany) for 30 min at 37°C in an incubator. Fibronectin has been removed before seeding 
the cells. Wells were filled either with control cells, HU induced senescent cells or with both 
cell types for co-culturing in duplicates or triplicates, respectively. Cells were seeded in 96-
well plates (1x105 cells/well in 200 µl medium), 24-well plates (2x105 cells/well in 1 ml 
medium) or 12-well plates (2x105 cells/well in 3 ml medium), incubated at 37°C in an 
incubator and analysed at the respective time points. Supernatants were collected and frozen 
at -20°C. Cells were washed one time with PBS, harvested with Accutase and resuspended 
in an appropriate volume of medium. Cell Counting was done in a Bürker-Türk counting 
chamber and an aliquot of each condition (control cells, HU induced senescent cells and co-
culture) has been used for preparation of 4 cytospins (2.5x104 cells/cytospin) which were 
frozen at -20°C. 1x105 cells were first washed and then resuspended in 50 µl FACS buffer. 
Surface marker GD2, MHC class I and CD44 were stained for FACS analysis (chapter 2.2.1). 
 
In the first experiment, for each time point two wells (duplicates) of a 96-well plate with flat 
bottom were seeded either with control cells, HU treated senescent cells (1x105 cells/well = 
200 µl) or for the co-culture  with both types of cells (5x104 cells per cell type/well = 100µl/cell 
type). For the second and third experiment wells were coated with fibronectin before cells 
were seeded, control cells were cultured in 24-well plates (2x105 cells/well) and wells were 
filled up to 1 ml with medium. For HU treated senescent cells and the co-culture a 12-well 
plate has been used with 2x105 cells/well in 3 ml medium.   
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2.1.4 Co-culture  of control, spontaneous or drug induced senescent cells and T-
cells 
For all experiments with T-cells either 96-well plates with round bottom (NuncTM, Roskilde, 
Denmark) or 24-well plates with flat bottoms (IWAKI Europe, Willich, Germany) were coated 
with anti-mouse IgG1 antibody (Sigma Aldrich, Vienna, Austria) for 2 hours at 37°C before 
use. For each setup, T-cells were thawed and seeded on the same day.  
 
2.1.4.1 Isolation of peripheral blood mononuclear cells 
Fresh Buffy Coat (Österreichisches Rotes Kreuz) was diluted 1:2 with room temperature 
PBS. For density gradient centrifugation diluted blood was cautiously layered over 10-15 ml 
Ficoll (LSM 1077 Lymphocyte, PAA, Pasching, Austria) and centrifuged for 30min at 300g at 
20°C without brake. Peripheral blood mononuclear cells (PBMCs) formed a ring in the 
interphase which was carefully transferred into a new tube and washed twice with PBS. Cells 
were resuspended in 50ml MACS buffer (PBS/0.5% BSA/2 mM EDTA) and 50µl were 
aliquoted for cell number measurement with a Sysmex Cell counter (Sysmex Europe, 
Norderstedt, Germany). 
For freezing of PBMCs, 1x108 cells were centrifuged, resuspended in 5ml medium and mixed 
with 5ml FCS/ 20% DMSO. This cell suspension was transferred into cryo tubes 
(1ml/tube=1x107 cells). Samples were frozen step-wise by cooling for 1-2 hours at -20°C and 
sub-sequent transfer to -80°C. To store cells for a longer period, they were moved to a liquid 
nitrogen tank. 
 
2.1.4.2 Column-based isolation of T-cells from PBMCs  
T-cells were isolated from human PBMCs by depletion of non-T cells (negative selection) 
using the Human Pan T Cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Pre-cooled solutions were used and cells were kept on ice, unless otherwise mentioned. All 
volumes of reagents used were calculated for 107 cells. Cells were centrifuged at 300 g for 
10 min at 4°C and resuspended in 1,6 ml MACS buffer. Non-T cells were indirectly 
magnetically labelled with 200µl of biotin-conjugated monoclonal antibodies, as primary 
labelling reagent. The Pan T-Cell Biotin-Antibody Cocktail contains antibodies directed 
against CD14 (macrophage marker), CD16 (Natural killer cells), CD19 (B-cell marker), CD36 
(platelet marker), CD56 (Natural killer cells), CD123 (plasmacytoid dendritic cell and basophil 
marker) and Glycophorin A (erythroid cell marker). Incubation took place for 10 min at 4°C. 
1.2 ml MACS buffer was added before cells were labelled with 400 µl anti-biotin monoclonal 
antibodies conjugated to MicroBeads, the secondary labelling agent, for 15 min at 4°C. Cells 
were washed with MACS buffer (10−20 x labelling volume) and centrifuged at 300 g for 10 
min. The cell pellet was resuspended in 3 ml MACS buffer. LS columns were placed in the 
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magnetic field of a suitable MACS Separator and columns were prepared by rinsing with 3 ml 
MACS buffer. Cell suspension was applied onto the columns (1 ml/column) and the effluent 
was collected as fraction with unlabelled cells. Columns were washed with 3x with 3 ml 
MACS buffer each and the entire effluent was collected in the same tube as before. This 
fraction represented the enriched T-cell fraction. T-cells were diluted 1:2 in medium and FCS/ 
20% DMSO. This cell suspension was aliquoted into cryo tubes (1x107 cells/tube) and frozen 
at -80°C. Aliquots before (PBMCs) and after (T-cells) depletion were taken to look for purity 
of the enriched T-cells by flow cytometry.  
 
2.1.4.3 CFSE labelling 
T-cells were thawed and washed twice with PBS at 1200 rpm, 7 min at 4°C before they were 
resuspended in PBS (107 cells/ml). 1 nM CFSE (Sigma-Aldrich, St Louis, MO, USA) was 
added, gently mixed and incubated for 10 min at 37°C. 5 ml FCS were added and incubated 
at RT for 5 min. Cells were washed twice with medium, 50 µl were removed after the first 
washing step for cell number measurement with the sysmex cell counter and cells were 
resuspended in medium, respectively. 
 
2.1.4.4 Anti-CD3 Titration  
Frozen T-cells were thawed, washed one time with PBS, resuspended in PBS and labelled 
with CFSE. The cell number was defined with the sysmex cell counter and the cell 
suspension was diluted with medium.  Cell suspensions were mixed with anti-CD3 antibody 
(Sigma-Aldrich, Germany) at 10 ng/ml, 25 ng/ml, 100 ng/ml and 250 ng/ml, respectively. The 
negative control contained no anti-CD3 antibody and for positive control 1 µg/ml 
Staphylococcal enterotoxin B (SEB, Sigma-Aldrich, St Louis, MO, USA) was added. Each 
condition was set up in triplicates in a 96-well plate (5x104 cells/well) which was incubated at 
37°C for 3, 4, 5 and 6 days, respectively. For FACS analyses, cells were transferred into 
micronic tubes (Szabo-Scandic, Vienna, Austria), washed and resuspended in 50 µl FACS 
buffer. 4 µl DAPI-solution (2 μl/ml dilution in 1xPBS, Sigma-Aldrich, Germany) was added 
and proliferation of T-cells was analysed with the BD LSRII Flow Cytometer (Becton 
Dickinson, USA) and using the FACS-Diva software. 
 
2.1.4.5 Co-cultivation of T-cells and neuroblastoma cells  
Three replicate wells were set up for each experimental group (control, spontaneous 
senescent cells, HU treated-, CPT treated- and BrdU treated senescent cells) together with 
T-cells at three NB:T-cell ratios, 1:1,1:5 and 1:10. T-cells were thawed, CFSE labelled and 
adjusted to 5x105 cells/ml in medium. 10 ng/ml anti-CD3 was added and 5x104 cells/well 
were transferred into IgG coated 96-well plates. The number of T-cells/well was always the 
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same, while the number of NB-cells was adapted depending on the NB:T-cell ratios. For 
negative control T-cells were not stimulated with anti-CD3 and for positive control T-cells 
were stimulated with 1 µg/ml SEB. 
Control, spontaneous senescent cells, HU treated-, CPT treated- and BrdU treated 
senescent cells were harvested, counted with the Bürker-Türk counting chamber and diluted 
with medium to appropriate concentrations in order to obtain the three different NB:T-cell 
ratios (end volume 200 µl/well). All surrounding empty wells were filled with PBS. Plates were 
incubated for 6 days at 37°C in an CO2-incubator. Co-culture supernatants were collected 
and frozen at -20°C and cells were analysed for T- cell proliferation (CFSE) and CD45, CD4, 
CD8 and CD25 with the BD LSRII Flow Cytometer (see chapter 2.2.2). 
 
2.1.4.6 Co-cultivation of T-cells with conditioned medium of neuroblastoma cells  
Control, spontaneous senescent cells, HU treated-, CPT treated- and BrdU treated 
senescent cells were plated in duplicates or triplicates, respectively, in a 96-well plate (5x104 
cells/well) one day before T-cells were plated for co-cultivation. Cells were incubated over 
night at 37°C in an incubator. 
T-cells were thawed, CFSE labelled and transferred into an IgG coated 96-well plate (5x104 
cells/well). Plates with NB-cells were shortly centrifuged, conditioned medium was 
transferred onto T-cells and anti-CD3 antibody was added (5 ng/ml). For negative control T-
cells were not stimulated with anti-CD3 and for positive control T-cells were stimulated with 1 
µg/ml SEB. 
 
Conditioned medium was transferred and anti-CD3 was added only on day 0 (for “1x 
transfer”) or daily, respectively. For daily supernatant transfer, wells with NB-cells were 
refilled with medium, incubated over night at 37°C and supernatant was transferred again 
onto T-cells the next day. This procedure was repeated every day until analysis. Plates were 
incubated for 6 days at 37°C and cells were analysed for T- cell proliferation (CFSE) and 
CD45, CD4, CD8 and CD25 with the BD LSRII Flow Cytometer (see chapter 2.2.2). 
 
2.1.4.7 Co-cultivation of T-cells and neuroblastoma cells in transwell plates 
Transwell plates (12 mm transwell with 0.4 µm Pore Polyester Membrane Insert, Corning) 
allow the co-culture of two different kind of cells without direct cell-cell contact, but with an 
exchange of cytokines produced by the cells through an microporous membrane. 
 
T-cells were thawed and CFSE labelled. In the lower compartment of a flat 24-transwell plate 
coated with anti-IgG 2x105 T-cells were added. In the upper compartment, 1x105 NB-cells 
(control, spontaneous senescent cells, HU treated-, CPT treated- and BrdU treated 
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senescent cells) were seeded. Wells contained 700 µl medium in total and 5 ng/ml anti-CD3 
was added. In addition, NB-cells and T-cells were plated together in the lower compartment 
without a transwell insert (“direct contact”). Reactions were set up in duplicates. Plates were 
incubated for 6 days at 37°C in an incubator and cells were analysed for T- cell proliferation 
(CFSE) and immuno-stained for CD45, CD4, CD8 and CD25, followed by FACS analysis 
with the BD LSRII Flow Cytometer (see chapter 2.2.2). 
 
 
 
Figure 6│Co-culture of different types of NB-cells and T-cells in transwells and in direct contact. 
 
 
2.2 Flow Cytometry 
The BD LSRII Flow Cytometer was equipped with three lasers (solid state lasers 405nm and 
488nm, He-Ne laser 635nm). The BD LSRFortessa cell analyser was equipped with four 
lasers (355nm, 405nm, 488nm and 640nm). The cytometer performance was checked 
weekly using SPHEROTM Ultra Rainbow fluorescent particles (Sperotech, Libertyville, US). 
For data evaluation the BD FACS DiVaTM (Becton Dickinson) software was used. Depending 
on the antibodies used, appropriate gating strategies were defined. 
 
A washing step is defined by adding 400µl FACS buffer (PBS, 0.05% sodium azide, 0.1% 
BSA), centrifugation at 1200rpm at 4°C for 5 minutes and discarding the supernatant. 
Samples were kept on ice throughout the staining procedure. DAPI solution (2μl/ml DAPI in 
1xPBS solution, Sigma-Aldrich, Germany) was added 5 minutes before measurement at the 
flow cytometer. 
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2.2.1 Immunostaining of GD2, CD44 and MHC I for FACS analysis 
For analysis of CD44, MHC I and GD2 (chapter 4.1.4.2: Flow-cytometry analysis of GD2, 
CD44 and MHC I and chapter 4.2: Functional Analysis- Co-culture of senescent and non-
senescent NB-cells) 105 cells were washed with FACS buffer and resuspended in 50µl FACS 
buffer. For the first staining step, 6 µl of 1:20 pre-diluted anti-GD2-FITC, 5 µl anti-CD44-PE 
and 3 µl anti-MHC I-biotin were added (see table 1). The cell suspension was mixed and 
incubated for 20 min at 4°C. Cells were washed with FACS buffer and resuspended again in 
50 µl FACS buffer before the second staining step. 10 µl anti-streptavidin-PerCP were 
added, mixed and incubated for 20 min at 4°C. After a further washing step, cells were 
resuspended in 50 µl FACS buffer, 4 µl DAPI solution was added and cells were analysed for 
cell proliferation and CD44, MHC I and GD2  using the BD LSRFortessa flow cytometer 
(Becton Dickinson). 
 
2.2.2 Immunostaining of CD45, CD4, CD8, CD25 for FACS analysis 
For analysis of CD45, CD4, CD8 or CD25 (chapter 4.3: Functional analysis-
immunomodulation) 105 cells were harvested, washed with FACS buffer and resuspended in 
50 µl FACS buffer. Cells were stained with 2,5 µl anti-CD4-PerCP, 2 µl anti-CD8-APCeFluor 
780, 2,5 µl anti-CD25-PE and 2,5 µl anti-CD45-APC (table 1), respectively. The cell 
suspension was mixed and incubated for 20 min at 4°C. Cells were washed with FACS 
buffer, resuspended again in 50 µl FACS buffer, 4 µl DAPI solution was added and cells were 
analysed for CFSE and CD45, CD4, CD8 or CD25  using the BD LSRII Flow Cytometer. 
 
 
Ab specificity Conjugate Dilution Used volume [µl] Company 
GD2 FITC 1:20 6 * 
CD44 PE 1:10 5 BD Bioscience** 
MHC I Biotin - 3 Abcam*** 
Streptavidin PerCP 1:100 10 BD Bioscience** 
CD4 PerCP - 2,5 BD Bioscience** 
CD8 APCeFluor 780 - 2 eBioscience**** 
CD25 PE - 2,5 eBioscience**** 
CD45 APC - 2,5 eBioscience**** 
 
Table 1│Antibodies used for flow cytometry (*purified anti-GD2 antibody, chimeric ch14.18, was 
kindly provided by Prof. Dr. med. Handgretinger, Universitätsklinikum Tübingen, Germany/ ** BD 
Bioscience, San Jose, CA, USA / *** Abcam, Cambridge, UK / **** eBioscience, San Diego, CA, USA) 
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2.3 Microscopy  
2.3.1 Senescence-associated β-galactosidase activity assay 
Cells were grown in a 6-well plate at a density of 5x105 cells/well. After washing cells one 
time with PBS the senescence detection kit (BioVision, Mountain View, USA) was used to 
stain for SA-β Gal activity. 1 ml Fixative Solution per well was added for 15 min at room 
temperature. Meanwhile the Staining Solution Mix (1 ml/well) containing 940 µl Staining 
solution, 10 µl Staining Supplement and 50 µl X-gal in DMF (20 mg/ml) was prepared. After 
cells were washed two times with PBS, they were covered with the freshly prepared Staining 
Solution Mix and incubated overnight at 37°C in an incubator. Next day, cells were rinsed 
with PBS, analysed with an Axiovert 40C inverted microscope (Zeiss, Austria) and 
photographed with PixeLINK software (Ottawa, USA). 200 cells positive for SA-β Gal activity 
(blue-staining) were counted. 
 
2.3.2 Cytospin preparation 
Cells were harvested with Accutase, resuspended in PBS and kept on ice until usage. Slide 
carriers, cytospin funnels, filter cards and slides were assembled and placed into the 
cytocentrifuge (Shandon, Cheshire, United Kingdom). Filters were pre-wetted with 50 µl of 
0,9% sodium chloride solution and centrifuged at 600 rpm for one minute. 50-200 µl (1-4x104 
cells per slide) of the cell suspension was distributed onto each slide by centrifuging 8 
minutes at 500 rpm. Filter and funnel were carefully removed without damaging the cells and 
the slide was air dried at least for one hour. Preparations were either used immediately or 
stored at RT for up to two weeks. To store cytospins for a longer period they were frozen at -
20°C in appropriate boxes. 
 
2.3.3 Double-target Fluorescent in situ hybridization to analyse MYCN-status 
The cell spot on cytospin slides was marked on the back of the slide using a diamond scribe. 
Slides were fixed in precooled (4°C) 4% paraformaldehyde (Roti-Histofix 4%, Roth, 
Karlsruhe, Germany) for 10-15 min. Then they were washed twice with 1xPBS for 5 min at 
RT, dehydrated in an Ethanol series (70%, 90%, 95% Ethanol; for each 2 minutes) and air 
dried in a rack. 1 µl of the nick-labeled probes, MYCN-dig and 2p-bio, were applied to the 
cells and a cover glass was sealed with rubber cement (Fixogum, Marabu, Tamm, Germany). 
For denaturation of target DNA and probe, slides were placed on a heating plate (Präzitherm, 
Störcktronic) at 78°C for 8 min. Hybridization was achieved through incubation in a moist 
chamber in a Haereus incubator at 37°C over-night. Next day, slides were washed for 5 
minutes in 2 x SSC at RT. Then they were placed two times 15 min into a tank with pre-
warmed 50% formamide in 2 x SSC at 42°C (in a water bath) and two times for 7 min  into a 
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tank with pre-warmed 2 x SSC at 42°C. For detection of the probes, antibodies against 
digoxigenin, and biotin were diluted in the same 2-3% BSA/PBS solution and 100 µl was 
applied to the hybridized area. The dilution factor used for mouse Cy3-conjugated  Anti-biotin 
(Dianova GmbH, Hamburg, Germany) was 1:800 and for sheep FITC-conjugated anti-
digoxigenin antibody (Roche Diagnostics GmbH, Mannheim, Germany) 1:200. Incubation 
was performed in a moist chamber at 37°C for 30-45 min followed by two washing steps 
(each 7 min) in 4 x SSC supplemented with 0.1% Tween20 at 42°C . Secondary antibodies in 
2-3% BSA/PBS solution were incubated in a moist chamber at 37°C for 30 min. Goat Cy3-
conjugated anti-mouse (Dianova GmbH, Hamburg, Germany) was diluted 1:500 and rabbit 
FITC-conjugated anti-sheep (Dianova GmbH, Hamburg, Germany) was diluted 1:200. The 
washing procedure described above was repeated and slides were dehydrated again through 
an ethanol series followed by air drying in the dark. Preparations were mounted with 10 µl 
Vectashield (Vector, Burlingame, Ca, USA) supplemented with DAPI and covered with a 
cover slip that was sealed with rubber cement (Marabu). Analysis was performed with an 
Axioplan fluorescence microscope (Zeiss, Austria) and images were processed with the Isis 
software (MetaSystems, Altlussheim, Germany). 
 
2.3.4 Probe (MYCN and 2p) labelling by nick translation  
The bacterial clones 08–103-1 (chromosome 2p) and RP11-355-H10 (AC010145, MYCN) 
were obtained from Dr. M. Rocchi (Resources for Molecular Cytogenetics, University of Bari, 
Italy).  2 µg of extracted template DNA was combined with either DIG-Nick Translation Mix 
(Roche, Vienna, Austria) containing 0.08 mM digoxigenin-11-dUTP for MYCN labelling or 
Biotin-Nick Translation Mix (Roche, Vienna, Austria) containing 0.08 mM biotin-16-dUTP for 
2p labelling. The total volume was adjusted to 40 µl with ddH2O. Incubation took place in a 
water bath at 16°C for 90 min.  Afterwards probe labelling and size (MYCN: 200 Kb) was 
verified by running 5 µl of the respective sample mixed with 1 µl loading buffer in a 1,2% 
agarose gel at 100 V and 500 mA. Meanwhile the probes were stored on ice to allow further 
nick labelling. 
The reaction was stopped by addition of 30 μg of COT human DNA (Roche Diagnostics 
GmbH, Mannheim, Germany), a volume of NaAc (3M, pH 5.5, Merck, Darmstadt, Germany) 
calculated as 1/10 of the probe volume plus the COT DNA volume and 2.5 times the volume 
of the solution of 100% Ethanol (Merck, Darmstadt, Germany). Labelled DNA probes were 
precipitated through a 30 min incubation reaction at -80°C followed by 30 min centrifugation 
at 13000 rpm at 4°C in a Hereaus Biofuge pico. The supernatant was discarded and the 
pellet resuspended in 70% Ethanol. The following centrifugation was done for 15 min at 
13000 rpm at 4°C. After the supernatant was again removed, the DNA pellet dried for 5 min 
at RT. Finally, the probe was resuspended in 40 µl of a hybridization mix (master mix 
contains 200 µl distilled water, 200 µl formamide, 100 µl 20x SCC and 200 µl dextransulfate) 
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and the DNA dissolved at 37°C in an thermomixer (Eppendorf, Germany). Probes were 
stored at 4°C. 
 
2.3.5 GD2 and CD44 Immunostaining on cytospins   
Cytospin slides were fixed in precooled (4°C) 4% paraformaldehyde (Roti-Histofix 4%, Roth, 
Karlsruhe, Germany) for 15 min. After washing two times with 1xPBS for 5 min each at RT, 
slides were incubated with the primary antibodies for 30-45 min at 37°C in a humid chamber. 
The mouse anti-human CD44 antibody (Bender MedSystems, Vienna, Austria) was diluted 
1:50 and the anti-human GD2-FITC antibody (purified anti-GD2 ch14.18 delta was kindly 
provided by Prof. Dr. med. Handgretinger, Universitätsklinikum Tübingen, Germany. FITC 
labelling of anti-GD2 was done in our group) 1:100 in 2-3% filtered BSA. After the slides were 
again washed two times with 1xPBS for 5 min each at RT, the Cy3-labeled goat-anti-mouse 
secondary antibody (Dianova GmbH, Hamburg, Germany) was applied at a 1:500 dilution 
with 2-3% filtered BSA for 30-45 min in a humid chamber at 37°C.  After two washing steps in 
1xPBS, slides were stained with a 2 μl/ml DAPI (Sigma-Aldrich, Germany) in 1xPBS solution 
for 1 min at RT. Slides were again washed two times for 5 min in 1x PBS to remove the DAPI 
solution. Finally, cells were covered with Vectashield (Vector, Burlingame, Ca, USA) and an 
adequate cover slip was sealed with Fixogum rubber cement (Marabu). Slides were 
examined with an Axioplan fluorescence microscope (Zeiss, Austria) and pictures were taken 
with a high resolution CCD camera with the ISIS software (MetaSystems, Altlussheim, 
Germany). 
 
 
2.4 Protein Analysis 
2.4.1 Western Blot 
Cells were harvested, centrifuged at 1200 rpm for 10 min and washed once with PBS before 
shock freezing the pellet in liquid nitrogen. After thawing, the cell pellets were lysed with 
RIPA  buffer (50 mM Tris.HCl pH7.4, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 150 mM 
NaCl, 2 mM EDTA, 50 mM NaF) containing phosphatase inhibitor sodium orthovanadate 
(Sigma S6508-10G) and protease inhibitor (Complete ETDA free, Roche) and dispersed by 
sonication (3 sec, 9 Cycles, 50% Power). Tubes were kept on ice during sonication to 
prevent heating of the sample. Afterwards, tubes were centrifuged for 15 min at 13.000 rpm 
and 4°C and the supernatant, containing the protein extract, was transferred to a fresh tube. 
Protein concentration of each sample was determined with a Bradford Assay (Biorad Protein 
Assay). The sample volume corresponding to 60 µg protein was calculated. All samples were 
filled up to the same volume with RIPA buffer, mixed with 4x loading buffer and boiled for 5 
min at 95°C. Samples were centrifuged for 2 min at full speed and loaded on a 8,5% or 10% 
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SDS PAGE (Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis) gel (see table 3) 
depending on the size of the protein to be assayed. Additionally 5 µl of pre-stained Page 
Ruler was loaded in one slot. The gels were submerged in 1x running buffer and the gel was 
run at 40V until samples reached the separating gel. Then the voltage was increased to 100V 
for 1.5 hours. Proteins on the gel were blotted onto a nitrocellulose membrane with 0.2µm 
pore size. Gel and membrane were sandwiched between sponge and paper and clamped 
together avoiding air bubbles. Blotting was achieved in 1x transfer buffer for 1.5 hours at 220 
mA. The proteins were visualized through staining with Ponceau for 7-8 min to determine if 
they have migrated uniformly and evenly. The Ponceau staining was scanned. Unspecific 
binding sites were blocked with 1x blocking solution (Roche) for at least 30 min under 
agitation at RT. The membrane was incubated with the primary antibodies diluted in 0.5% 
blocking solution over night at 4°C shaking. The blots were washed 2 times for 10 min with 
TBST and 2 times for 10 min with 0.5% blocking solution. Secondary antibodies were diluted 
in 0.5% blocking solution and pipetted on the membrane. Incubation was performed for one 
hour at room temperature in the dark under agitation. Antibodies and the concentrations used 
are depicted in table 4. Membranes were washed three times for 10 min with TBST and once 
for 10 min with TBS. Measurement of the fluorescence was performed with the LI-COR 
ODYSSEY system. Chemiluminescence was detected using the Femto-chemiluminescence 
detection kit (Thermo Scientific, USA), light-sensitive films and a film developer. 
 
RIPA buffer 
PBS containing 5mM EDTA, 1% NP40, 1% deoxycholate, and  
2% SDS, with 1x protease inhibitor mix 
10x running buffer 30,3g Tris base pH 8,3, 144g Glycine, 10g SDS in 1L dH2O 
1x running buffer 1:10 dilution of 10x running buffer 
10x transfer buffer 140g Glycine, 30g Tris base 1L dH2O 
1x transfer buffer 100 ml 10xTransferbuffer, 700ml dH2O and 200ml Methanol 
Maleic Acid Buffer 
5,8g Maleic Acid (100mM), 4,38g NaCl (150mM), adjust pH to 
7,5 with NaOH and steril filter 
10x Blocking Solution 10g Blocking Reagent in 100ml Maleic Acid Buffer (autoclaved) 
1x / 0,5x Blocking Solution 1:10 / 1:20 dilution of 10x Blocking solution with TBS 
10x TBS 60,57g Tris-HCl pH 7,5 and 43,83 g NaCl (1,5M) in 500ml dH2O 
1x TBS 1:10 dilution of 10x TBS 
1x TBST 1:10 dilution of 10x TBS + 1ml Tween-20 in 1L 
 
Table 2│Buffers and solutions used for Western Blot 
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Table 3│Recipes for Stacking and Running Gel. * Rotiphorese Gel 30, Carl Roth, Germany 
 
 
Table 4│Antibodies used for Western Blot 
 
 
2.5 Statistics 
Data are presented as means ± standard deviation above and below the mean. Statistical 
analysis was conducted using Microsoft Office Excel 2010. A paired, 2-tailed Student t test 
was used to determine the statistical significance of differences between two analysed 
groups.  Values of P < 0.05 were considered significant. 
 
 
 
 
 
 
 
 
 
 
 
 
Reagent
Stacking Gel 
8,5%
Stacking Gel 
10%
Seperating Gel
30 % Acrylamide mix * 1,4 ml 1,65 ml 0,415 ml
Aqua dest. 2,28 ml 2,025 ml 1,7 ml
Tris (1.5 M, pH 8.8) 1,25 ml 1,25 ml -
Tris (1 M, pH 6.8) - - 0,315 ml
20% SDS 25 µl 25 µl 12,5 µl
10% APS 50 µl 50 µl 25 µl
TEMED 3 µl 3 µl 2,5 µl
1. Ab against dilution species Company 2. Ab against dilution Company
Cdk2 (M2) 1:500 rabbit Santa Cruz biotechnology GαRb red 1:10.000 LI-COR
GAPDH 1:1000 mouse Santa Cruz biotechnology GαM green 1:10.000 LI-COR
n-Myc 1:50 mouse Abcam GαM green 1:10.000 LI-COR
p16 (F-12) 1:100 mouse Santa Cruz biotechnology αRb-HRP 1:10.000 Femto-Kit
p53 (DO-1) 1:1000 mouse Santa Cruz biotechnology GαM green 1:10.000 LI-COR
phospho p53 
(Ser15)
1:350 rabbit Cell Signaling αRb-HRP 1:10.000 Femto-Kit
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3 Aim of the study 
 
(1) In the first part of our study, we aimed to analyse whether camptothecin and 
bromodeoxyuridine have the ability to induce senescence faster than hydroxyurea in 
MYCN amplified neuroblastoma cells in vitro and whether these treated cells differ in 
morphology, growth behaviour, MYCN status and marker expression from control and 
spontaneous senescent F-cells.  
 
We have recently observed that long-term low-dose-treatment with the chemotherapeutic 
agent hydroxyurea (HU) induces senescence in primary neuroblastoma cell lines in vitro.  
Senescence induction with HU takes 8-10 weeks. To find other drugs which are able to 
induce senescence in a shorter period of time we tested camptothecin (CPT) and 
bromodeoxyuridine (BrdU) on MYCN amplified (MNA) neuroblastoma cells. We investigated 
changes in morphology, which could be indications of senescence, by microscopy. Next, we 
stained treated and untreated NB cultures for SA-β-Gal to confirm the senescence induction 
in HU, CPT and BrdU treated NB-cells and to quantify the number of senescent cells in these 
cultures. MYCN copy number was analysed by fluorescent in situ hybridization (FISH) in 
order to investigate, whether HU, CPT and BrdU treatment leads to a reduction of MYCN 
amplification in the nucleus, and therefore would acquire the characteristic of a less 
aggressive type of NB-cells. Furthermore we examined the abundance of the NB tumour 
marker GD2, known to be low after HU treatment, and expression of CD44, known to be up-
regulated after HU treatment, by immunofluorescence and FACS in control, spontaneous 
senescent and drug induced senescent cells. We previously described that NB-cell lines, 
negative for MHC I, up-regulate MHC I surface expression in spontaneously occuring 
senescent cells and in response to HU. We then wanted to know, if expression of the MHC 
class I molecule changes also after treatment with CPT and BrdU and therefore analysed the 
differently treated NB-cells via FACS. To study candidate pathways involved in senescence 
of spontaneous senescent cells and drug induced senescent cells we analysed the 
expression and in part the phosphorylated/activated forms of key mediators of senescence 
by Western Blot.  
 
 
(2) In the second part of our study, we asked whether senescent neuroblastoma cells 
modulate the proliferative capacity and tumour marker expression of non-senescent 
neuroblastoma cells in vitro. 
 
The senescence-associated secretory phenotype (SASP) has been described as the 
secretion of numerous cytokines, growth factors and proteases by normal and tumourigenic 
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(premature) senescent cells. SASP components have been shown to trigger both beneficial 
and unfavourable effects, probably depending on the cell type and physiological context. For 
instance, some secreted factors can induce proliferation arrest and senescence in malignant 
cells to prevent tumour development. However, SASP can also stimulate regeneration and 
repair of tissues after damage and thus can promote proliferation in nearby cells. These 
ambivalent facts raised the question, whether senescent NB-cells modulate the proliferative 
capacity and the expression pattern of GD2, CD44 and MHC I in non-senescent 
neuroblastoma cells in vitro. To investigate this, we assessed a co-culture experiment with 
control and HU treated senescent NB-cells. Cells were counted and expression of GD2, 
CD44 and MHC I was monitored by FACS staining, in weekly intervals.  
 
 
(3) In the last part of our study, our aim was to test whether senescent neuroblastoma 
cells differ from non-senescent neuroblastoma cells in their capability to stimulate T-
cell proliferation/activation in vitro. 
 
Previous publications have reported that neuroblastoma cells are poorly immunogenic. For 
instance they lack MHC I expression and thus inhibit T-cell activation in vitro and in vivo.  As 
senescence leads to a change of the expression profile in NB-cells, we posed the question:  
Do senescent NB-cells allow T-cell proliferation in vitro? 
Functional analyses were carried out to test the response of CD4+ and CD8+ T-cells to 
senescent versus non-senescent NB-cells. We co-cultured T-cells and NB-cells (either 
control cells, spontaneous senescent cells, HU-, CPT- or BrdU induced senescent cells) for 6 
days and looked for the percentage of cells that had proliferated within the CD4+ and CD8+ 
fraction by FACS analysis. Further, we wanted to know, if secreted or cell bound factors play 
a role. Thus we analysed if the supernatant of NB-cells is sufficient to trigger an effect on T-
cell proliferation. For this, on the one hand conditioned medium of NB-cells has been 
transferred to T-cells, and on the other hand co-cultures in transwell plates have been carried 
out and again proliferation of cells within the CD4+ and CD8+ population was measured by 
FACS analysis. Additionally, we looked for the T-cell activation marker CD25 in the transwell 
experiment. 
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4 Results 
4.1 Characteristics of induced senescent neuroblastoma cells in vitro 
In this part of our study we wanted to investigate whether CPT and BrdU treatment of MNA 
neuroblastoma cell lines lead to senescence, as shown in long-term HU treated NB-cells, in 
vitro. Further we wanted to know, if those drug treated NB-cells are similar to spontaneous 
senescent F-cells and HU treated senescent cells and whether they differ in morphology, 
growth behaviour, SA-β-Gal staining, MYCN copy number and GD2, CD44 and MHC I 
expression compared to control cells. 
 
The two neuroblastoma cell lines STA-NB 10 and NB-Ma, used in this study, have been 
established from high risk tumours of neuroblastoma patients, which show MNA appearing 
as dmin. We have described previously, that low dose treatment with the micronuclei-
inducing drug HU over 6-8 weeks induces senescence, apoptosis and differentiation in MNA 
NB-cell lines [125]. In order to identify a drug, which induces senescence in a shorter period 
of time, several NB-cell lines were treated with potential senescence inducing drugs. Short 
term cell survival was measured by MTT assay at day 3 and day 5 and IC50 values were 
determined. Based on this assay, we investigated the effect of camptothecin (CPT) and 
bromodeoxyuridine (BrdU) at IC50 concentrations (determined at day 5) on the two 
neuroblastoma cell lines STA-NB 10 and NB-Ma in a longterm experiment.  
CPT is an anticancer drug, which targets the enzyme topoisomerase I and arrests cells in G2 
phase. Treatment with CPT has been shown to trigger rapid apoptosis in some cell types 
(e.g. HeLa) [168]. However low doses of CPT can also induce a senescence-like-phenotype 
as observed in a human colon cancer cell line [88].  
BrdU is a thymidine analogue that is incorporated into replicating DNA. Originally, it was 
designed to disturb DNA synthesis in cancer cells [169]. BrdU has been shown to induce a 
senescence-like phenotype in normal and immortal mammalian cells in vitro [170, 171] and in 
NB-cell lines [172]. Therefore it was chosen as positive control for in vitro experiments. 
 
4.1.1 Growth behaviour and cell morphology  
To look for changes of morphology and growth behaviour of drug treated NB-cells and 
compare them to control cells and spontaneous senescent F cells, control cells (CTRL) of the 
cell lines STA-NB 10 and NB-Ma were treated either with 150 µM HU, 5 nM CPT or 20 µM 
BrdU for 3-10 weeks, respectively (Fig. 7).  
Control cells primarily consist of N-cells, small cells with scant cytoplasm and neurite 
outgrowth (Fig. 7A). Sporadically, spontaneous F-cells, cells with flat morphology and high 
granularity, were found in the control populations (Fig. 7A), but their frequency was 
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significantly lower than in drug treated populations (Fig. 7C-E). Spontaneous senescent F-
cells were purified as described in materials and methods. In both cell lines spontaneous F-
cells showed a senescent morphology and strongly slowed down their proliferation (Fig. 7B). 
 
 
 
Figure 7│Morphology of STA-
NB 10 and NB-Ma cells before 
and after drug treatment 
Images of control cells (CTRL), 
spontaneous senescent F-cells 
(sp.F), 3 weeks CPT treated cells, 
3 weeks BrdU treated cells and 8-
10 weeks HU treated cells were 
taken using phase contrast 
microscopy. 
(×10 magnification) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HU treatment of STA-NB 10 cells led to a decrease of N-cells in the culture. In the first week 
after induction many cell debris were present in the medium, but there were still a lot of N-
cells in the culture. After continuous induction with HU more and more senescent F-cells 
appeared in the culture while the amount of N-cells further went down. Further, some of the 
remaining N-cells clustered and developed long outgrowths connecting other N-cell clusters 
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in the surrounding. These neurite networks resembled typical structures of differentiating 
neuroblastoma cells. After 8-10 weeks of weekly HU induction only a few sporadic N-cells 
remained next to a high number of senescent F-cells (Fig. 7E). HU treatment of NB-Ma was 
not included in this diploma study, but was done at a later time point in the group of Peter 
Ambros. 
Upon CPT treatment both cell lines responded similar. In the first week a high number of N-
cells died, but after 2-3 weeks the frequency of senescent F-cells increased, nevertheless 
compared to HU treated cells there were less F-cells present per culture flask. The cells 
became more granulated and larger compared to the HU treated cells. After 3 weeks, mainly 
F-cells were present in the culture (Fig. 7C). 
Similarly, treatment with BrdU led initially to cell death in both cell lines. 2-3 weeks later the 
number of N-cells had decreased strongly and large adherent senescent F-cells were 
observed (Fig. 7D). After BrdU treatment the morphology and density of F-cells was more 
similar to HU treated cells than to the CPT treated cells. The proportion of the three cell types 
(N-cells, F-cells and differentiating cells) varied between different flasks and different 
inducing drugs, but generally cells with neurite extensions declined over time. 
 
4.1.2 SA-β-Gal Activity 
Senescence-associated β-galactosidase (SA-β-Gal) is the most consistent and widely used 
marker for senescent cells, which is defined as beta-galactosidase activity detectable at pH 
6.0 in senescent cells [61]. SA-β-Gal activity is typically measured by staining with the 
substrate X-gal, which forms a perinuclear blue precipitate upon cleavage [173]. Thus 
senescent cells can be recognized due to their blue appearance after SA-β-Gal staining. 
 
To prove senescence in NB-cells, SA-β-Gal activity was assayed on: control cells, 
spontaneous senescent F-cells, 3 weeks CPT treated cells, 3 weeks BrdU treated cells and 
8-10 weeks HU treated cells (Fig. 8). 
In both NB-cell lines the small N-cells were found to be SA-β-Gal negative, whereas F-cells 
were mostly positive for SA-β-Gal staining. Control flasks contained only 0-3% SA-β-Gal 
positive senescent cells (Fig. 8A and Fig. 9). Interestingly, the percentage of SA-β-Gal 
positive cells in spontaneous senescent F-cells differed strongly between the two NB-cell 
lines. In the STA-NB 10 cell line only 12% of SA-β-Gal positive cells were found (Fig. 8B, left 
panel and Fig. 9), while in the NB-Ma cell line 86% of the cells showed the blue SA-β-Gal 
staining (Fig. 8B, right panel and Fig. 9).  
All drug induced senescent NB-cells of both cell lines acquired a strong blue SA-β-Gal 
staining indicating that they entered the senescent pathway (Fig. 8C-E). CPT induced cells 
showed 94-98% and BrdU induced cells displayed 88-90% SA-β-Gal positive cells. With 76% 
the HU induced STA-NB 10 cells showed slightly less SA-β-Gal positive cells compared to 
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cells treated with CPT or BrdU (Fig. 9). The SA-β-Gal results are in accordance to the 
senescence morphology observed in these cells. 
 
For reasons of simplicity pre-senescent and senescent cells are summarized under the term 
senescent cell or senescent F-cell. 
 
 
 
Figure 8 │SA-β Gal staining of 
STA-NB 10 and NB-Ma cells 
before and after drug treatment  
Control cells (CTRL), 
spontaneous senescent F-cells 
(sp.F), 3 weeks CPT treated cells, 
3 weeks BrdU treated cells and 8-
10 weeks HU treated cells were 
stained for SA-β Gal. Cell images 
were taken using bright field 
microscopy. (×10 magnification) 
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Figure 9 │ Quantification of SA-β Gal positive cells in STA-NB 10 and NB-Ma cells 
The percentage of SA-β-Gal positive cells in cultures of control cells (CTRL), spontaneous senescent F-cells 
(sp.F), 3 weeks CPT treated cells, 3 weeks BrdU treated cells and 8-10 weeks HU treated cells was 
determined by counting blue stained cells. In total 200 cells each were counted under the bright field 
microscope (mean ± s.d. of number counted by three persons; ** shows significance at the P ≤ 0.01 level 
compared to CTRL). 
 
4.1.3 MYCN copy number 
To investigate, if HU, CPT and BrdU treatment lead to a reduction of MYCN amplification in 
the nucleus, which would indicate that NB-cells turn into non-amplified cells known to be less 
aggressive in NB tumours,  MYCN copy number was analysed by fluorescence in situ 
hybridization (FISH). 
 
FISH was used to evaluate MYCN status in neuroblastoma [174]. This technique was applied 
on cytospin preparations of control cells, spontaneous senescent F-cells and treated cells, 
respectively (Fig. 10 and Fig. 11). A probe specific for the short arm of chromosome 2 (2p) 
was used as reference probe for MYCN FISH. Cells with MYCN amplification, which is 
defined as at least 4-times increased MYCN copy number compared to the 2p reference 
probe, were counted and the percentage of MNA cells was calculated for each condition and 
cell line (Fig. 12).  
 
In control cell preparations of STA-NB 10 and NB-Ma the small round shaped nuclei 
contained strongly amplified MYCN copies (Fig. 10A and Fig. 11A). Visual inspection 
revealed a high number of green signals spread over the whole nucleus. In contrast, there 
were only two red signals for the reference probe indicating chromosome 2 disomy. 
Altogether, 90-92% of the control cells were MYCN amplified (Fig. 12).  
In spontaneous F-cells of both cell lines most nuclei are bigger and more elongated 
compared to control nuclei. These cells had much less MYCN copies in both cell lines and 
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the MYCN signals were often found in clusters at the border of the nucleus (Fig. 10B and Fig. 
11B).  
 
 
Figure 10 │ MYCN copy number analysis in cells of STA-NB 10 
FISH for MYCN (green) and 2p reference (red) and DAPI staining (blue) for nucleus identification on control 
cells (CTRL), spontaneous senescent F-cells (sp. F), 3 weeks CPT treated cells, 3 weeks BrdU treated cells 
and 8-10 weeks HU treated cells. (White bar=10 µM) 
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Figure 11 │ MYCN copy number analysis in cells of NB-Ma 
FISH for MYCN (green) and 2p reference (red) and DAPI staining (blue) for nucleus identification on control 
cells (CTRL), spontaneous senescent F-cells (sp. F), 3 weeks CPT treated cells, 3 weeks BrdU treated cells 
and 8-10 weeks HU treated cells. (White bar=10 µM) 
 
Further, DAPI positive micronuclei densely packed with MYCN copies were frequently seen 
in the proximity of a nucleus. The percentage of cells having MNA was clearly decreased to 
53-59% in spontaneous senescent F-cell populations (Fig. 12).  
Similar to spontaneous senescent F-cells the nuclei of CPT, BrdU and HU treated senescent 
cells were larger than the nuclei of control cells. Notably, senescent cells display a higher 
autofluorescence in the cytoplasm due to the formation of autofluorescent lysosomal storage 
bodies known as lipofuscin [175]. 
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CPT treated senescent cells showed a reduced number of MYCN copies (Fig. 10C and Fig. 
11C). 47% of the CPT treated STA-NB 10 cells (Fig. 12, left panel) and 59% of the CPT 
treated NB-Ma cells (Fig. 12, right panel) were MYCN amplified. There remained still some 
N-cells in the culture when the cytospins were prepared, thus a direct comparison of N-cells 
(small round nuclei with many MYCN copies) and induced senescent F-cells (larger nuclei 
with less MYCN copies) can be seen on some slides (Fig. 10C).  
FISH on BrdU treated cells was technically difficult, as BrdU incorporation probably hampers 
proper binding of the FISH probes. Thus MYCN and 2p signals were missing in the majority 
of nuclei and it was not possible to accurately quantify cells with MNA (BrdU treated STA-NB 
10 are absent in Fig. 12, left panel). Nevertheless, in the small number of cells with both 
probes present, a reduction of MYCN copies was observed (Fig. 10D). In the NB-Ma cell line 
FISH on BrdU treated cells was successful showing a drastic reduction of the MYCN copy 
number in the majority of nuclei. The number of cells with supernumerical MYCN copies 
dropped down to 56% (Fig. 12, right panel).  
As expected FISH on HU treated senescent STA-NB 10 cells revealed a low copy number of 
MYCN in the nuclei (Fig. 10E). Only 40% of cells with MNA remained in the cell population 
after HU treatment (Fig. 12, left panel). In summary, spontaneous senescent F-cells and cells 
treated with CPT, BrdU and HU revealed a strong reduction of MNA cells compared to 
control cells. 
 
 
 
Figure 12 │ Quantification of cells with MYCN amplification in STA-NB 10 and NB-Ma cells 
The percentage of MNA cells in control cells (CTRL), spontaneous senescent cells and drug induced 
senescent cells was evaluated by counting nuclei with 4-times increased  MYCN FISH signals compared to 
the 2p signal within 100 nuclei in total. All data are mean values ± s.d. of the number of MNA cells counted 
by two persons (* shows significance at the P ≤ 0.05 level compared to CTRL; n=3).  
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4.1.4 Analysis of GD2 level, CD44 and MHC I expression  
We have previously shown that in primary NB-cultures N-type cells show high levels of the 
NB tumour marker GD2 and lack CD44 and MHC I staining. In contrast, GD2 is down-
regulated and CD44 and MHC I are up-regulated in spontaneous senescent F-cells and after 
HU treatment [125]. To study whether CPT and BrdU treated senescent cells differ in marker 
expression from control, spontaneous senescent F-cells and HU treated senescent cells, we 
first analysed GD2 and CD44 on cytospin preparations by immunofluorescence staining and 
second, studied and quantified cells containing these markers by FACS fluorescence 
together with MHC I. 
 
4.1.4.1 Immunofluorescence staining of GD2 and CD44 
Control cells of both cell lines were strongly positive for GD2 and completely negative for 
CD44 with the exception of some sporadic F-cells between the N-cells (Fig. 13 and Fig. 14). 
In contrast, spontaneous senescent F-cells and all drug treated senescent cells (no matter 
which drug was used for treatment) showed the opposite immunostaining with almost no 
signal for GD2 and a strong signal for CD44. Similar to the FISH images, a higher 
cytoplasmic autofluorescence was visible in senescent cells compared to control cells. 
However this yellow/greenish staining could be clearly distinguished from a normal mostly 
membrane-associated GD2 signal. In HU induced STA-NB 10 cells (Fig. 13) a few strong 
GD2 (green) stained N-type cells were visible next to strongly CD44 (red) stained senescent 
cells, exemplifying that GD2 and CD44 expression are exclusive on the majority of cells (Fig. 
13 and Fig. 14).  
 
4.1.4.2 Flow-cytometry analysis of GD2, CD44 and MHC I 
To determine the percentage of cells positive for MHC I, CD44 or GD2 in untreated and drug 
treated senescent NB-cells, cells were immunostained and analysed by flow-cytometry. First 
we analysed the cells in forward scatter (FSC) versus side scatter (SSC). Next we gated for 
DAPI negative cells to omit dead cells. Viable cells were then depicted in a MHC I versus 
GD2 dot plot. Thereafter MHC I positive and MHC I negative cells were plotted for CD44 
versus GD2, respectively (Fig. 15). 
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Figure 13 │ STA-NB 10 cells were stained for DAPI, GD2 and CD44 
Control cells (CTRL), spontaneous senescent F-cells (sp.F), CPT-, BrdU- and HU treated senescent cells 
were immunostained with anti-GD2-FITC (green), anti-CD44-TRITC (red) and DAPI on cytospin 
preparations. (White bar=10 µM) 
 
 
 
51 
 
 
Figure 14 │ NB-Ma cells were stained for DAPI, GD2 and CD44 
Control cells (CTRL), spontaneous senescent F-cells (sp.F), CPT- and BrdU- treated senescent cells 
were immunostained with anti-GD2-FITC (green), anti-CD44-TRITC (red) and DAPI on cytospin 
preparations. (White bar=10 µM) 
 
 
Senescent cells, both spontaneous and drug induced, showed higher SSC values, indicating 
higher granularity, compared to control cells (Fig. 15, left panel). Interestingly, CPT treated 
senescent cells displayed an even higher SSC and FSC, a measure for cell size, compared 
to all other conditions (Fig. 15, left panel). Further, control cells showed more dead cells and 
cell debris (DAPI+) compared to senescent cells (Fig. 15, second panel from left). The gate 
for DAPI- cells has been adapted for spontaneous senescent F-cells and all drug treated 
senescent cells, due to their higher autofluorescence.  
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Figure 15 │ STA-NB 10 cells were stained for DAPI, GD2, CD44 and MHC1 and analysed by FACS 
Cells were gated on DAPI negative cells to exclude dead cells. In the next step these cells were gated on 
MHCI+ and MHCI- cells, which were then separately displayed in a dot plot with CD44 on the y-axis and GD2 
on the x-axis. Analysis was performed using the BD LSRFortessa cytometer. Data were evaluated using the 
BD FACS DiVa software. (One representative experiment of 3 is shown) 
 
 
In the STA-NB 10 cell line more MHC I+ CD44+ cells can be seen in spontaneous senescent 
F-cell cultures (ranged between 70-97%), HU treated cells (ranged between 94-99%), CPT 
treated cells (~87%) and BrdU treated cells (~52%) compared to control cells (ranged 
between 3-27%). After BrdU treatment a high number of MHC I- GD2+ cells could be 
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detected in the culture (ranged between 43-49%) (Fig. 15, second panel from right and Fig. 
16, left panel). 
Similar results were found in the NB-Ma cell line. The percentage of MHC I+ GD2- cells was 
clearly higher in spontaneous senescent F-cells (ranged between 43-84%), CPT treated (58-
93%) and BrdU treated (82-91%) cells compared to control cells (2-7%) (Fig. 16, right panel). 
 
 
 
Figure 16│ Quantification of MHC I- GD2+/- and MHC I+ CD44+ cells by FACS analysis 
The diagrams show the percentage of indicated cell populations in control (CTRL), spontaneous senescent 
F-cells (sp.F), CPT-, BrdU- and HU treated STA-NB 10 and NB-Ma cell lines. (Results from one 
representative experiment out of 3 are shown) 
 
 
For all conditions, the majority (>92%) of MHC I+ cells was CD44+ (representing senescent F-
cells). In control and spontaneous senescent F-cells almost all MHC I- cells were CD44 
low/intermediate (>95%). Notably, the percentage of CD44- cells within the MHC I- GD2+/- 
cells was reduced in treated cells (55% in CPT ind., 64% in BrdU ind. and 83% in HU ind. 
cells). Thus not all MHC I- cells were also CD44- (Fig.15, right panel). 
 
In summary, we could show that treating MNA neuroblastoma cells for 3 weeks with CPT and 
BrdU turned them into enlarged adherent cells which became senescent. Thus, senescence 
induction of MNA NB-cells with CPT and BrdU was faster compared to HU induction, which 
took 8-10 weeks. Further, we could confirm senescence in all drug treated NB-cells by SA-β-
Gal staining. Moreover, both cell lines displayed a decrease of MYCN copy number in 
spontaneous senescent cells and all drug treated senescent cells. Finally, we could see that 
GD2 level was reduced and CD44 and MHC I expression was increased in spontaneous 
senescent cells and all drug treated senescent cells compared to control cells. 
 
4.1.5 Analysis of the senescence pathway  
To study which senescence pathway is activated in spontaneous senescent cells and in HU, 
CPT and BrdU treated senescent STA-NB 10 cells we analysed the expression of the key 
mediators of the senescence pathways such as CDK2, p16, p53 and phospho-p53 (Ser15) 
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(as phosphorylation of p53 is associated with activation) by western blotting of whole cell 
lysates. Additionally, we studied the MYCN protein level to see whether the expression 
changes with the reduction of MYCN copy number in spontaneous senescent cells, HU-, 
CPT- and BrdU-treated senescent cells (Fig. 17). 
MYCN expression was detected only in control cells, but not in senescent cells, which is in 
line with the reduced MYCN copy number seen in senescent cells. The CDK2 level was 
markedly down-regulated in all senescent cells compared to control cells. Furthermore, an 
accumulation of p16 could be observed in spontaneous senescent cells and in CPT and 
BrdU induced cells but not in HU induced cells which showed p16 levels similar to that in 
control cells. The expression of phospho-p53 was slightly up-regulated in spontaneous 
senescent cells and cells becoming senescent upon CPT treatment (Fig. 17; the upper 
strong band which can be seen in control cells is an unspecific band). The amount of total 
p53 was slightly higher in control cells (Fig. 17).  
 
  
 
Figure 17│ Western Blot of samples obtained after drug treatments of STA-NB 10 cells 
Control cells (CTRL), spontaneous senescent F-cells (sp.F), HU induced, CPT induced and BrdU induced 
cells were collected and whole cell lysates were taken for Western blot. SK-N-MC (SK) cells (Ewing 
Sarcoma cell line) were additionally analysed and used as control for p53. Antibodies against MYCN, CDK2, 
p16, phospho-p53 and p53 were used. GAPDH demonstrates the loading control as it is constitutively 
expressed in almost all tissues at high levels. 
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4.2 Functional Analysis: Proliferation in co-cultures of senescent and non-
senescent neuroblastoma cells 
To observe whether senescent NB-cells modulate the growth behaviour and tumour marker 
expression of non-senescent neuroblastoma cells and vice versa we co-cultured control cells 
and HU induced senescent cells in one well. In addition, control cells and senescent cells 
were grown separately in distinct wells to compare the results with those of the co-culture.  
Senescent cells were labelled with CPD, a cell dye, incorporating in the cell membrane, in 
order to be able to distinguish them via FACS from control cells which were CPD negative. 
We preferred to stain senescent cells instead of control cells with CPD because senescent 
cells should keep the CPD labelling longer than control cells due to their very low proliferation 
rate. Control cells proliferate faster, so their CPD intensity halves with every cell division. Cell 
number and expression of GD2, CD44 and MHC I was monitored at day 0, 2, 7, and 14. 
Supernatants were collected and frozen for future studies. Cytospins were prepared and 
frozen for future stainings. 
 
In the first experiment, for each time point two wells (duplicates) of a 96-well plate with flat 
bottom were seeded either with control cells or HU treated senescent cells (1x105 cells/well) 
or for the co-culture with both types of cells (5x104 cells per cell type/well). For the second 
and third experiment wells were pre-coated with fibronectin and control cells were seeded in 
24-well plates (2x105 cells/well). HU induced senescent cells and the co-culture was seeded 
in 12-well plates. 
 
In experiment 1 control and senescent cells had a similar proliferation curve until day 7 (Fig. 
18A). At the beginning cells showed little proliferation, then the number of cells fell to a lower 
cell number than on day 0. Cells in the co-culture proliferated and reached a three times 
higher cell number compared to day 0. Most of the cells dyed after day 7, thus there are no 
data for later time points. In the second and third experiment, bigger wells were used to 
ensure that the cells obtain enough medium for cell growth and wells were coated with 
fibronectin before seeding for better cell-attachment to the bottom of the wells. Both 
experiments ended after the analysis on day 14. 
In experiment 2 the same cell number was observed on day 0 and on day 2. Moreover, cells 
proliferated between day 2 and 14. Control cells expanded 2.5 fold until day 7 and 4 fold until 
day 14. In HU treated senescent cultures the cell number stayed constant until day 7 and 
then increased their cell number 2.5 fold until day 14. Cells in the co-culture expanded very 
fast until day 7, but then died until the next analysis on day 14 and reached the same cell 
number as on day 0. Experiment 3 showed nearly the same trend until day 2. Thereafter, 
control cells started to proliferate and had a 4 fold higher cell number on day 14 compared to 
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day 0. Senescent cells did not proliferate, some cells even died. Cells in the co-culture 
doubled until day 7 and stayed almost the same until day 14. In summary, it was not possible 
to cultivate cells in co-culture for more than 2 weeks at this experimental setup. Further, all 
three experiments yielded different proliferation curves which were not conclusive. 
 
 
 
 
Figure 18 │ Co-culture of control cells and HU induced senescent cells from the STA-NB 10 cell line  
Control cells and senescent cells were cultivated separately and in co-culture to measure proliferation (A) 
and MHC I expression (B) of cells in each condition after 2, 7 and 14 days. Results of three independent 
experiments are shown. 
 
 
CPD negative control cells contained mainly N-cells, but also a small population of F-cells 
which were shifted to the right side presumably because of their higher auto fluorescence 
(Fig. 19). The majority (80%) of the senescent cells were clearly CPD positive. The other part 
of the senescent cells was neither CPD negative nor clearly CPD positive. In comparison to 
the N-cells of the control cells they were more distributed and shifted to the right. As 
expected a mixture of these two populations was visible in the co-culture: Two defined 
populations, CPD negative and CPD positive are clearly distinguishable, representing control 
and CPD labelled senescent cells. This picture changed when cells that were longer in co-
culture were analysed. Cells which were CPD positive on day 0 moved to the left and 
interfered with the unstained cells. Therefore, it was not possible to definitely separate CPD 
positive and negative cells. Thus the CPD staining was not accounted for further analysis.  
 
57 
 
Instead, we analysed MHC I positive, CD44 positive, GD2 negative cells in the total DAPI 
negative (alive) population. Percentages of MHC I positive cells in control, senescent and 
control plus senescent cells are shown in figure 18 B (results of three independent 
experiments). In all three experiments control cells contained only 0-5% MHC I positive cells 
and this did not change throughout the whole experimental period. Senescent cultures 
started with 60-83% and cells in the co-culture well with 44-70% MHC I positive cells. 
Regarding senescent cells, there was an increase from 60% to 78% MHC I positive cells in 
experiment 1. In experiment 2 MHC I positive cells increased little (from 67% to 76%) before 
the percentage dropped to 31% until day 14. In contrast, in experiment 3 MHC I positive cells 
decreased from 83% to 76% until day 7 and then increased to 93% until day 14. Notably, co-
cultured cells showed a decrease of MHC I positive cells in all experiments. 
 
 
Figure 19 │ CPD staining 
One example of a co-culture experiment on day 0, when looking for the CPD staining by FACS is shown. 
Control cells (CTRL, unstained), senescent cells (CPD stained) and control+ senescent cells (both cell types 
mixed together in a 1:2 ratio) were first gated for DAPI negative cells to eliminate dead cells before they were 
visualized in a SSC versus CPD plot. 
 
 
4.3 Functional Analysis: Immunomodulation  
Neuroblastoma cells are poorly immunogenic. For instance they lack MHC I expression and 
thus inhibit T-cell activation in vitro and in vivo.  As senescence leads to a change of the 
expression profile in NB-cells, we wanted to study whether senescent NB-cells modulate T-
cell proliferation in vitro. 
 
4.3.1 Anti-CD3 Titration 
Mature T-cells recognize and react to the antigen/ MHC complex through their antigen-
specific receptors (TCR). T-cells can be antigen independently activated upon in vitro 
stimulation via antibodies to the TCR. In order to test a possible influence of senescent or 
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control NB-cells on T-cell activation, we aimed to activate T-cells by using an anti-CD3 
antibody. Thus, anti-CD3 was titrated in a CFSE based T-cell proliferation assay. For this 
purpose a titration study using different concentrations of an anti-CD3 (10 ng/ml, 25 ng/ml, 
100 ng/ml and 250 ng/ml) was performed and proliferation was measured on day 3, day 4, 
day 5 and day 6 (descripted in detail in chapter 2.1.4.4).  
 
With every cell division CFSE labelled cells halve their CFSE intensity. Therefore cells that 
have proliferated can be seen as peaks with a lower CFSE intensity (shifted to the left) in a 
count vs. CFSE plot and every peak is equivalent to one cell division (Fig. 20, right panel).  
 
 
 
Figure 20 │ Gating-Strategy for CFSE labelled proliferating T-cells 
First we gated for single cells and then excluded cell debris in the FSC-SSC plot. Next, gates were set to 
exclude DAPI positive (dead) cells. Finally, a gate for T-cells that have proliferated was defined (the peak on 
the very right side represents non-proliferating cells). 
 
 
Proliferation of T-cells was determined at day 3 to day 6 upon activation with 10 - 250 ng/ml 
anti-CD3 (Fig. 22). When using 10 ng/ml, on day 3 no proliferation was detected. On day 4 T-
cells started to proliferate and on day 6 already more than half of the T-cells showed 
proliferation (Fig. 21). 
 
 
Figure 21 │ T-cell proliferation analyses  
An example of FACS plots of CFSE labelled T-cells after 3 to 6 days of culture with 10 ng/ml anti-CD3. 
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All concentrations of anti-CD3 tested, led to an activation of T-cell proliferation, ranging from 
25 to 54% (Fig. 22) and except for 25 ng/ml anti-CD3 the amount of proliferated cells was 
highest on day 6 (Fig. 22). For the following experiments we used 10 ng/ml anti-CD3 and 
analysed on day 6, because T-cells were nicely stimulated, but not over stimulated, at these 
conditions. 
 
 
Figure 22 │Titration of anti-CD3 concentration and time-course of CFSE based proliferation assay 
CFSE labelled T-cells were activated with different concentrations of anti-CD3 as shown and incubated for 3, 
4, 5 or 6 days before they were analysed by flow cytometry. The percentage of CFSE negative (proliferating) 
cells was determined. 
 
 
4.3.2 Co-culture of T-cells and neuroblastoma cells 
To study whether NB-cells (control, spontaneous senescent, HU treated senescent, CPT 
treated senescent and BrdU treated senescent cells) modulate the proliferation of T-cells, 
these cell types were co-cultured and T-cell proliferation was determined.  NB-cells were 
mixed with T-cells at a ratio of 1:1, 1:5 and 1:10 in a 96-well plate. Different ratios were used 
to see if the effect is concentration dependent. The maximum proliferation of T-cells was 
achieved 6 days after activation with 10 ng/ml anti-CD3 (as shown in chapter 1.2.1; Fig. 22). 
As for subsequent experiments we aimed at analysing a possible immune-modulatory effect 
of NB-cells on T-cells, an even lower concentration of 5 ng/ml antiCD3 was selected and 
cultures were harvested and FACS analysed at day 6. For FACS analysis, we first gated for 
single cells, then we excluded cell debris before gating for DAPI negative cells (as described 
in Fig. 20). In a next step gates were set on CD4+ and CD8+ cells and within these two 
populations the percentage of CFSE- (proliferating) cells was determined. The experiment 
was accomplished two times. The first experiment contained all types of drug induced 
senescent NB-cells (Fig. 23 A) whereas in the second experiment CPT induced senescent 
cells were not included (Fig. 23 B). 
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Figure 23 │ Proliferation of CD8+ and CD4+ T-cells after 6 days in co-culture with different treated NB-
cells. NB-cells generated under different culture conditions were compared for their capacity to stimulate T-
cell proliferation. Analysis was done on day 6 of co-culture. 5ng/ml anti-CD3 was used for activation of T-
cells. Results of two independent co-culture experiments (A and B) are shown. 
 
 
T-cells activated with anti-CD3 alone (negative control) showed 14-19% proliferation in 
experiment 1 (Fig. 23 A) and almost no proliferation (1-4%) in experiment 2 (Fig. 23 B). In 
both experiments the proliferation of T-cells (both CD4+ and CD8+) was higher when they 
were cultivated together with senescent cells compared to control cells (Fig. 23). At the 1:1 
NB to T-cell ratio 58-74% of CD8+ cells proliferated in the presence of senescent cells in 
experiment 1 (Fig.  23 A) and 43-58% in experiment 2 (Fig. 23 B), whereas the proliferation 
rate of CD8+ cells co-cultivated with control cells was only around 10%. CD8+ cells had a 
considerable higher proliferation rate than CD4+ cells in both experiments. At a ratio of 1:1 
around 2% of CD4+ cells co-cultured with control cells proliferated. In co-cultures with 
senescent NB-cells CD4+ cells showed a proliferation of 13-26% in experiment 1 (Fig. 23 A) 
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and 5-33% in experiment 2 (Fig. 23 B). The level of CD8+ T-cell proliferation in the presence 
of senescent cells (which were induced by different drugs) slightly varied between 
experiments, but they all presented the same trend in up-modulating the CD8+ proliferation. 
The proliferation was always highest in wells with the 1:1 NB:T-cell ratio. With a decreased 
cell number of senescent NB-cells (1:5 and 1:10 NB:T-cell ratio) there was also a decline of 
CD8+ proliferation (Fig. 23 A). CD4+ cells generally proliferated less in the presence of 
senescent NB-cells compared to CD8+ cells, however the same trend was observed. In 
summary, senescent NB-cells facilitate T-cell proliferation and this effect is cell number 
dependent.  
 
 
4.3.3 T-cells cultured with conditioned medium from neuroblastoma cells 
To test whether the effect of NB-cells on T-cell proliferation is cell contact dependent or 
independent we looked for the proliferation of T-cells in the presence of conditioned medium 
produced by control or senescent NB-cells (control, spontaneous senescent, HU treated 
senescent, CPT treated senescent and BrdU treated senescent cells). The experiment was 
set up as in the co-culture experiment aforementioned in a 6-day assay except that NB-cell 
conditioned medium was used instead of NB-cells.  
 
Experiment A and B were performed in parallel to the co-culture experiment 1 (Fig. 23A), 
which means that parallel approaches included NB-cells from the same flasks/preparations 
and T-cells from the same batch. For each condition triplicates were done, except for some 
cases in which the cell number of NB-cells was insufficient. In those cases duplicate wells 
were set up. 5x104 cells/well were seeded. After one day control or senescent NB-cell 
conditioned medium was transferred onto T-cells either one time or daily. 
 
In experiment A (Fig. 24 A) anti-CD3 activated T-cells and T-cells with control-cell 
conditioned medium achieved almost the same percentage of CFSE negative T-cells (around 
17% of CD8+ and 25% of CD4+).T-cells, including both CD4+ and CD8+ cells, grown in 
conditioned medium from all types of senescent NB-cells presented a slightly decreased 
proliferation (between 5-17%). However, in this experiment, cells generally proliferated less 
than previously observed.  
 
NB-cells produce and secret cytokines continuously when they are in direct co-culture with T-
cells. Therefore, we wanted to know whether these factors affect the proliferation of T-cells. 
However, transfer of NB-cell conditioned medium (CM) only on day 0 does not expose the T-
cells continuously to factors produced by NB-cells as they would encounter in a direct co-
culture. To compensate for this problem, CM produced by control or senescent NB-cells 
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(control, spontaneous senescent, HU treated senescent, CPT treated senescent and BrdU 
treated senescent cells) was transferred daily to T-cells in experiment B (Fig. 24B). In the 
positive control (T-cells + anti-CD3) 67-72% T-cells proliferated. T-cells treated with CM from 
all NB-cell types (CTRL, Fsp, HU, CPT and BrdU) displayed only slight differences in 
proliferation (between 75-92%). CD4+ cells generally showed a proliferation rate comparable 
to those of CD8+ cells (Fig. 24B).  
 
 
 
Figure 24│ T-cell proliferation after transfer of conditioned media from NB-cells to T-cells  
Two experiments are shown. Conditioned medium either from control cells (CTRL), spontaneous senescent 
F-cells (Fsp), HU treated senescent, CPT treated senescent or BrdU treated senescent cells was transferred 
to T-cells. For negative and positive control normal medium was used. In experiment (A) conditioned 
medium was transferred only one time (on day 0). In experiment (B) daily transfer of conditioned medium 
and anti-CD3 was carried out. Reactions were set up in duplicates or triplicate, respectively. NB-cells of exp. 
(A) and exp. (B) are from the same flasks/preparations and T-cells from the same batch. Experiments were 
done in parallel. 
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Both experiments showed similar results. There was almost no difference in T-cell 
proliferation when co-cultured with control cells or senescent NB-cells. However, experiment 
A and experiment B differed in the proliferation efficiency of T-cells, probably because in 
experiment A cells were stimulated only once with anti-CD3 on day 0, whereas cells in 
experiment B were stimulated every day by daily addition of anti-CD3, which caused a higher 
proliferation rate.   
 
4.3.4 Co-culture of T-cells and neuroblastoma cells in a transwell plate 
None of the previously described supernatant transfer experiments could mimic a co-culture 
situation where NB-cells and T-cells do not have the possibility of direct cell contact, because 
additional steps had to be done like supernatant transfer, which dilutes components that are 
produced by T-cells, or anti-CD3 addition to maintain the original concentration. A more 
accurate method to prove if the effect on T-cell proliferation is cell-cell contact dependent or 
cell contact independent is the cultivation of T-cells and NB-cells (CTRL, Fsp, HU, CPT or 
BrdU) in a transwell assay. Therefore, T-cells and NB-cells were either separated by a 
transwell membrane or grew without transwell separation in a direct co-culture for 
comparison. The NB:T-cell ratio was 1:2 and cells were cultivated for 6 days (described in 
detail in chapter 2.1.4.7). 
For FACS data evaluation, we gated for single cells, excluded cell debris and then gated for 
DAPI negative cells. Further CD4+ and CD8+ cells were gated separately and analysed for 
CFSE. Within these two populations the percentage of cells having proliferated was 
determined via a CFSE intensity and activation of CD4+ and CD8+ cells was measured by 
determining the percentage of cells positive for CD25, a marker present on activated T-cells.  
 
The positive control displayed very weak T-cell proliferation (2%). T-cells in direct co-culture 
with control cells showed 6% and separated through a transwell about 2% proliferation. In 
direct co-culture with senescent NB-cells 50-64% T-cells proliferated whereas in transwells 
there were only 2-3%. Both, proliferation and activation, of CD8+ cells are highly increased in 
wells with direct co-culture of T-cells and all types of senescent NB-cells (Fsp, HU, CPT and 
BrdU) whereas the same combination of cells in transwells showed similar proliferation and 
activation values as the positive control containing only T-cells and anti-CD3 without NB-cells 
(Fig. 25 and Fig. 26). 
The bars for the activation marker CD25 presented the same trend as the proliferation bars. 
14% of T-cells in the positive control showed CD25 expression, in co-culture with control 
cells 19% were activated and in trans-wells only 13%. In direct co-culture with senescent NB-
cells 55-66% of T-cells expressed CD25 compared to only 10-14% under transwell 
conditions. 
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Figure 25 │ Proliferation of CD8+ cells after direct co-culture and co-culture in transwells of NB-
cells and T-cells. Senescent NB-cells (Fsp, HU, CPT and BrdU) permitted strong proliferation of CD8+ 
cells in direct co-culture but not in transwells. 
 
 
Figure 26 │Activation of CD8+ cells after direct co-culture and co-culture in transwells of NB-cells 
and T-cells.  Senescent NB-cells (Fsp, HU, CPT and BrdU) led to strong CD25 expression of CD8+ cells in 
direct co-culture but not in transwells. 
 
 
The same tendency in proliferation and activation was visible for CD4+ cells as for CD8+ 
cells, but the values were lower (Fig. 27 and Fig. 28). 20-32% of CD4+ T-cells in direct co-
culture proliferated, only around half as many as in CD8+ cells. 29-44% CD4+ T-cells 
expressed CD25 compared to over 55% in CD8+ cells. In general, CPT induced senecent 
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NB-cells permitted a little bit less proliferation and activation of both CD8+ and CD4+ T-cells 
compared to spontaneous senescent F-cells, HU- and BrdU induced senescent cells.  
Taken together, T-cells proliferated and showed the activation marker CD25 only in direct co-
culture with senescent NB-cells, but not in the respective trans-well assay. 
 
 
Figure 27 │Proliferation of CD4+ cells after direct co-culture and co-culture in transwells of NB-cells 
and T-cells.  Senescent NB-cells (Fsp, HU, CPT and BrdU) permitted proliferation of CD4+ cells in direct co-
culture but not in transwells. 
 
 
 
Figure 28 │Activation of CD4+ cells after direct co-culture and co-culture in transwells of NB-cells 
and T-cells. Senescent NB-cells (Fsp, HU, CPT and BrdU) led to strong activation (CD25 expression) of 
CD4+ cells in direct co-culture but not in transwells 
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5 Discussion 
In this study, we showed that, next to treatment with HU, senescence can also be induced by 
treating MNA neuroblastoma cells with CPT and BrdU in vitro and that triggering senescence 
with these two drugs is faster compared to HU (only 3 weeks compared to 8-10 weeks). A 
shorter senescence induction time means, that CPT and BrdU are more efficient compared 
to HU in vitro. Treatment of NB-cells with any of the 3 drugs arrested tumour cell growth and 
induced senescence, confirmed by SA-β-Gal staining. Moreover, we could show a decrease 
of MYCN copy number and GD2 level and an increase of CD44 and MHC I expression in 
these drug treated senescent cells and in spontaneous senescent cells compared to control 
cells. The CD44 and MYCN status are similar to less aggressive forms of NB-tumors. 
Searching for the senescence pathway activated in senescent NB-cells, we found that p16 is 
increased in spontaneous senescent cells and in CPT and BrdU treated senescent cells, but 
only slightly in HU treated senescent cells. Therefore we suspect that different drug 
treatments may induce different senescence pathways. Whether senescent NB-cells alter the 
proliferation rate of non-senescent NB-cells still remains an open question. Finally, we found 
that senescent NB-cells were able to modulate the immune system by allowing an increased 
proliferation of CD8+ cells compared to non-senescent NB-cells. This might play an 
important role in cancer pathology. 
 
5.1 Characteristics of drug induced senescent neuroblastoma cells in vitro 
Spontaneously occurring senescent F-cells and HU induced senescent cells demonstrate 
similar biological characteristics which were previously described by our group [125, 126]. In 
this study we found that long term treatment with low doses of HU, CPT and BrdU induced 
senescence in MNA neuroblastoma cells of the cell line STA-NB 10. In NB-Ma HU treatment 
showed no effect on the cell proliferation, while CPT and BrdU also induced senescence. 
After induction with CPT more NB-cells died and therefore less senescent cells remained 
after 2-3 weeks compared with HU and BrdU induction. Furthermore, those remaining cells 
were strongly granulated. So it is very likely that the amount of DNA damage caused by CPT 
was more extensive than that caused by HU or BrdU. Comparing the features of 
spontaneous senescent F-cells, HU-, CPT- and BrdU induced senescent cells we found that 
all these cells demonstrated a similar senescent morphology. Thus, induction of senescence 
by HU, CPT and BrdU probably represents an acceleration and increase of the 
spontaneously occurring senescence taking place in cell culture. However, all three drugs 
induced, beside senescence and apoptosis, also differentiation in the first weeks of induction.  
Looking at the SA-β-Gal staining we saw that both spontaneous senescent F-cells and 
induced senescent cells showed a high percentage of SA-β-Gal positive cells, while control 
cells had only very few SA-β-Gal positive cells. Comparing spontaneously occurring and drug 
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induced senescent cells we observed that the percentage of SA-β-Gal positive cells was 
higher in the latter. Curiously the percentage of SA-β-Gal positive cells in spontaneous 
senescent cells of the STA-NB 10 cell line was much less (12%) compared to the NB-Ma cell 
line (86%). This could be explained by the occurrence of morphologically flat cells in the 
STA-NB-10 cultures that have not yet terminated the senescence process, thus are not 
efficiently stained by SA-β-Gal staining. In line with this it has been shown by others that the 
classical SA-β-Gal protocol, which is widely used, is actually not adequate to identify all 
senescent cells neither in vitro nor in vivo [176]. Therefore it is advisable to identify 
senescent cells by more than one method. 
MYCN amplification usually indicates an aggressive neuroblastoma tumour with rapid 
progression and a poor outcome [20]. In our experiments all kind of senescent NB-cells 
showed a clearly reduced MYCN copy number. Thus, senescent NB-cells lost genetic 
markers associated with aggressive tumour growth through the treatment with HU, CPT and 
BrdU. Although generally correlating, a low MYCN copy number could still be accompanied 
by high MYCN protein expression and vice versa [177, 178]. Our group showed that extra 
chromosomally amplified MYCN copies can be expulsed spontaneously by micronuclei 
formation [126] and that this phenomenon can be enhanced through low dose HU treatment 
[125]. In addition, HU is known to cause DNA ds breaks, thus triggering the DNA-damage 
repair pathway (DDR) [179]. As CPT and BrdU also induce DNA ds breaks, it is anticipated, 
that in NB-cells these substances trigger senescence through an impaired DDR. 
Camptothecin, a topoisomerase inhibitor, is known to induce DNA damage in human colon 
cancer cells by disrupting the DNA replication machinery. Treatment with low concentrations 
of CPT causes cells to undergo senescence. For this senescence development p21 has 
been shown to be required [88]. Recently, it was found that MYCN amplified neuroblastoma 
cells are more sensitive to camptothecin than MYCN negative cells and that camptothecin 
caused selective down-regulation of MYCN expression [180]. Our Western blot showed that 
control cells displayed not only the highest MYCN copy number, as shown by FISH 
experiments, but also the highest expression of the MYCN protein, while HU, CPT and BrdU-
treated senescent cells showed no detectable MYCN expression. Whether CPT treatment in 
NB-cells preferentially selects for cells with low MYCN copy number or leads to a MYCN-
amplicon reduction or direct down-regulation of MYCN expression remains to be elucidated. 
However, high numbers of micronuclei containing MYCN amplicons have been observed in 
CPT and BrdU-treated NB-cells (data not shown) which could explain the reduced MYCN 
copy number in senescent NB-cells. Importantly, independent of the underlying mechanism, 
MYCN copy number and MYCN protein expression are both low in HU, CPT as well as in 
BrdU-treated senescent NB-cells.  
BrdU is a thymidine analogue that incorporates into DNA and is commonly used in the 
detection of proliferating cells in tissues [181]. Moreover, BrdU has been shown to increase 
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the sensitivity of treated cells to ionizing radiation [169]. BrdU is suggested to increase the 
risk of mutations and double-strand breaks by altering the stability of DNA [182], but it should 
be mentioned that most of these effects appear only when BrdU treatment is combined with 
secondary stressors, such as ionizing radiation. In the absence of secondary stressors BrdU 
is thought to operate relatively mild as a thymidine analogue [181]. Recently it was published 
that a single brief in vitro treatment with BrdU induces an intense and constant reduction in 
the proliferation rate of all cancer cells examined (e.g. human cutaneous T-cell lymphoma, 
human osteosarcoma, rat glioma) and that those cancer cells show some signs consistent 
with senescence (e.g. SA-β-Gal activity) as they arrest in the G1 phase of the cell cycle 
[181]. Despite of this, BrdU is currently not considered as alternative drug to be included in 
NB treatment protocols because of high toxicity expected in young children. 
Together with the expression of SA-β-Gal and the MYCN copy number reduction, the number 
of CD44 positive cells increased in cells treated with HU, CPT and BrdU and in cells with 
spontaneous senescent F-cells. Neuroblastomas positive for CD44 are usually low stage 
tumours with favourable prognosis [138]. Thus, drug treatment with HU, CPT and BrdU 
reduces the aggressive characteristics of neuroblastoma cells and up-regulate CD44 and 
MHC I. 
 
When cells enter senescence, they become flattened, enlarged and multinucleated. 
Moreover many vacuoles can be found in the cytoplasm which leads to an increased cellular 
complexity. It is published that this distinctive senescent morphology can be seen by flow 
cytometry as increased side scatter [124]. This change was also visible in our experiments 
where spontaneous and treated senescent cells showed an increased side scatter. Further, 
analysis of GD2, CD44 and MHC I by FACS showed that spontaneous senescent-cells and 
CPT, HU and BrdU treated cultures contained a higher percentage of MHC I+ CD44+ cells 
compared to control cells. In line with the results of the GD2/CD44 immunofluorescence 
staining, GD2+ cells were decreased in all senescent cultures compared to control cells. All 
MHC I+ cells were also CD44+, but not all MHC I- cells were CD44-. The percentage of CD44- 
cells within the MHC I- GD2+/- cells was reduced in drug treated cells. It can be speculated 
that those CD44+ cells started already their senescence program after drug treatment, while 
their MHC I expression was still low. Quantification clearly shows that the frequency of MHC 
I+/CD44+ cells was high and the frequency of MHC I- GD2+/- cells is low in both cell lines in 
spontaneous senescent-cells and upon treatment with CPT, HU and BrdU.  
So far, our findings demonstrated no remarkable difference between spontaneously 
occurring and CPT-, BrdU- and HU induced senescent cells in MNA NB-cells. All senescent 
cells resembled in morphology, SA-β-Gal staining, MYCN copy number and showed high 
expression of the markers CD44 and MHC I and low levels of GD2. Thus, CPT-, BrdU- and 
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HU treatment of MNA NB-cells in vitro induces characteristics similar to a non-aggressive 
form of NB-tumours in these cells. 
Generally tumour rejection is mediated most notably by CTL, but human cancer cells usually 
try to escape CTL-mediated immune surveillance by low/absent expression of MHC I 
molecules. Thereby they evade to present target epitopes on the cell surface which are 
important for the immune recognition by CTL [183]. As long term low dose treatment of MNA 
neuroblastoma cells with CPT, HU and BrdU leads to up-regulation of MHC I molecules in 
our experiments, these senescent cells should be more efficiently recognized by CTL. This 
strategy of senescence induction could therefore reduce or prevent tumour progression 
especially in the minimal residual disease setting. An autologous cytotoxicity assay using 
senescent versus control NB-cells as target cells and autologous CTL as effector cells would 
clarify this issue. 
 
In search of the senescence pathways activated in drug induced senescent NB-cells, we 
found that different drugs induce either the p16 or an alternative senescence pathway. 
Western blot results show that p16 is overexpressed in BrdU- and CPT treated senescent 
cells and in spontaneous senescent cells, but only slightly in HU treated senescent cells 
compared to control cells. Thus, p16 seems to play a role in senescence induction after 
treatment with CPT, BrdU and probably HU and in spontaneous senescent cell.  
Moreover, CDK2 and MYCN are down-regulated in all senescent cells compared to control 
cells. MYC oncoproteins (including c-Myc and N-Myc) are known to be involved in 
development of several types of cancer. MYC encodes a pleiotropic transcription factor that 
primarily induces apoptosis by induction of p19Arf, which stabilizes p53 [184]. Wu et al. 
recently showed that the suppression of the c-Myc oncogene induces cellular senescence in 
several tumour types (e.g. lymphoma, osteosarcoma, hepatocellular carcinoma) [97]. 
Further, it was shown that depletion or inhibition of Cdk2 forced cells expressing Myc/Ras 
into cellular senescence [185]. Molenaar et al. demonstrated that silencing of Cdk2 by RNA 
interference induced apoptosis in MYCN amplified NB-cell lines, but no apoptosis was 
observed 48h after MYCN silencing [186]. Based on these studies it can be speculated, that 
cells may go into senescence when MYCN and CDK2 are down-regulated. This assumption 
fits to our Western blot results showing that Cdk2 and MYCN were low/absent in 
spontaneous and drug-induced senescent NB-cells.  
Total p53 was similar in control and senescent NB-cells, but significantly lower as compared 
to a Ewing sarcoma cell line, SK-N-MC. Similarly, phospho-p53 levels were equally low in 
control and senescent NB-cells and high in the SK-N-MC cell line. From previous 
experiments we know however, that HU-treatment induces total p53 levels and concomitant 
p53 phosphorylation at Ser15 3-5 days after treatment start. At later time points (4 weeks, 8 
weeks) no phospho-p53 was detectable. This fits to a senescence model published by 
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Roninson et al. which suggests that p53 is up-regulated early upon senescence induction 
and is then down-regulated, whereas p16 is upregulated later and is then required for 
maintaining the senescence phenotype, e.g. the SASP [124]. 
In human erythroleukemia K562 cells it is published, that HU treatment for 7 days or more 
changed the morphology of these tumour cells into a senescent like phenotype. Further, 
those HU treated cells possessed a positive SA-β-Gal staining and an accumulation of cdk 
inhibitors, such as p16, p21 and p27 [90]. One of those findings, the p16 accumulation after 
HU treatment, is in contrast to our experiment, which showed only weak p16 accumulation in 
HU treated senescent NB-cells. The two other cdk inhibitors, p21 and p27, should be 
analysed in further studies in treated and untreated MNA NB-cells. However the effect of the 
same drug may vary in tumour cells derived from different tissues. 
It has been shown that low concentrations of CPT induce DNA damage in human colon 
cancer cells causing cells to senesce [88]. Further it is known that molecular events caused 
by treatment with CPT mostly deal with stress response and pathways for cell survival 
activated by DNA damage [187]. In response to the Topo I inhibition, caused by CPT, two 
pathways have been described to play a role: the ATM/Chk2 DNA damage checkpoint 
pathway and the ATR-Chk1 response [188]. CPT has also been shown to activate NF-kB, an 
important transcriptional factor regulating the survival response [189]. Independently, after 
CPT exposure p16 has also been shown to accumulate quickly in vitro and in vivo [190]. The 
last finding is in line with our western blot results, which show p16 accumulation also in CPT 
treated senescent NB-cells.  
A study in lung cancer cells, that express wild-type p53, but no p16, showed that BrdU 
induces phenotypic changes that resemble senescence. BrdU treatment evoked a DNA 
damage response which involved the activation of Chk1, Chk2 and p53. Further an up-
regulation of p27 has been found [191]. Thus BrdU is able to induce senescence also 
independent of the p16 pathway, which we assume to be one of the crucial pathways 
underlying drug-induced senescence in MNA neuroblastoma cells. 
 
5.2 Functional Analysis: Co-culture of senescent and non-senescent 
neuroblastoma cells 
In preliminary experiments of our group the growth rate and GD2 level were found to be 
reduced in co-cultures of senescent together with non-senescent NB-cell lines compared to 
non-senescent cells alone. However, due to technical problems we could not reproduce 
these results in this study. First, N-cells easily detached from the bottom of the wells after 
seeding and always required some days to recover from manipulation during cell seeding. In 
general control cells grew much better in culture flasks than in 96-, 24- or 12-well plates. In 
order to improve attachment, wells were coated with fibronectin, but still attachment was not 
 
71 
 
comparable with the situation in culture flasks. In general N-type-cells started to proliferate 
faster after seeding in the presence of some spontaneous senescent F-cells, probably 
because senescent cells produce more extracellular matrix proteins which improve 
attachment of both cell types. In contrast to control cells, senescent cells quickly attach to the 
plastic surface of all kind of plates or flasks. Thus, control cultures containing a higher 
percentage of spontaneous senescent cells had an initial advantage in proliferation due to 
faster attachment. Second, control cells were not completely free of senescent cells and 
drug-treated cultures contained small, but varying amounts of N-type cells, which made it 
difficult to prepare repeated co-cultures with the same ratio of N-type and senescent cells. 
Third, we were not able to continue the co-culture experiment over a period longer than 2 
weeks, because thereafter viability in control cells dropped and they had to be re-seeded. 
Another critical point was the CPD staining which was done to track senescent cells and 
therewith their expression changes of MHC I. Unfortunately, it was not possible to separate 
senescent and non-senescent cells with this staining, as the CPD intensity dropped in 
senescent cells already after a few days, without having proliferated. Thus, our plan to 
monitor CPD negative control cells and learn if they acquire MHC I or CD44 during co-
cultivation with senescent cells was not feasible. 
As senescent cells produce ROS and secret various factors, such as interleukins, growth 
factors and enzymes that degrade extracellular matrix, it has been proposed that they can 
shape their local microenvironment and stimulate (tumour) cell growth, invasiveness and 
angiogenesis [65, 192, 193]. However a recently published study demonstrated the effect of 
senescent fibroblasts on their normal (proliferation-competent) corresponding cells. Via cell-
cell contact through gap junctions and ROS involving processes senescent fibroblasts induce 
a DNA damage response in nearby fibroblasts in vitro. As a result those bystander cells 
become also senescent. This effect, which describes the spreading of senescence towards 
neighbouring senescent cells, was named senescence-induced senescence [194].  
Due to the experimental setup and technical difficulties, we could not study this effect of 
senescence-induced senescence in our co-cultures. Therefore the experimental setup must 
be optimized for future studies.  
 
5.3 Functional Analysis: Immunomodulation of T-cells through 
neuroblastoma cells 
We could clearly demonstrate that the senescent NB-cells allow T-cells to proliferate much 
better than they do in co-culture with control cells. This effect could be seen with all kinds of 
senescent cells (spontaneous F-cells, HU- , CPT-, and BrdU induced cells) and it was most 
pronounced in the CD8+ T-cells. There are two possibilities how NB-cells could influence T-
cell proliferation: either senescent cells activate proliferation actively or non-senescent cells 
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inhibit proliferation. Previous studies using diphtheria-toxin, an antigen-dependent T-cell 
activation model, has shown that components of NB-cells, i.e. GD2, can inhibit T-cell 
proliferation [195]. Thus, control cells, which produce high levels of GD2 may actively 
suppress T-cell activation, whereas senescent cells, having reduced GD2 may allow T-cell 
activation or even facilitate T-cell activation by an additional, unknown mechanism. 
Furthermore we could detect a NB to T-cell ratio dependent decline of CD8+ T-cell 
proliferation from 1:1 to 1:5 and further to 1:10. Thus, the influence on T-cell proliferation is 
dependent on the cell number of NB-cells. 
By transwell experiments we could clearly see that direct contact of NB-cells and T-cells is 
required to induce efficient CD8+ and CD4+ T-cell activation and proliferation. The effect on 
CD4+ T cells was considerably below that on CD8+ T-cells. Moreover, we proved again that 
senescent NB-cells enhance T-cell proliferation compared to control cells. 
In our first attempts to analyse the role of secreted factors on T-cell activation, we either once 
or daily transferred NB-cell conditioned medium to T-cells. After one time transfer of NB 
conditioned medium (CM) on day 0, proliferation of T-cells was lower than previously 
observed, and CM from senescent cells led to a slight decrease of proliferating T-cells. When 
CM from NB-cells was transferred daily to T-cells, proliferation of T-cells was very high (up to 
88%) for all conditions and control cells showed similar results as senescent cells. These 
results suggest that the conditions in experiment A with one time transfer of NB conditioned 
medium (CM) on day 0,were not sufficient for T-cell proliferation and in experiment B daily 
transfer of NB conditioned medium plus daily replenished anti-CD3 led to an overstimulation 
of T-cells. Furthermore, in the assay with the daily transfer of conditioned medium T-cells 
could also secrete factors which can influence the proliferation, but those were diluted in our 
experiment through the process of medium transfer. In general, the situation in a co-culture 
cannot be imitated by transfer of conditioned medium. Consequently we decided to use 
transwell plates, which allow co-culturing of cells without cell-cell contact. Finally, further 
experiments should clarify if those T-cells that have proliferated are cytotoxic T lymphocytes 
(CTLs) or may contain CD8+ regulatory T-cells (Tregs). It would be also of interest how 
effective CTLs can kill senescent NB-cells compared to control cells in an allogeneic setting.  
In the co-cultivation experiments with T-cells and NB-cells, T-cells activated with anti-CD3 
showed generally a very low proliferation (~1-20%) compared to the anti-CD3 titration results 
(54%). Actually, the percentage of proliferating T-cells should be similar, because the 
experimental setup was the same. One explanation for the observed discrepancies could be 
the fact that the IgG antibody for coating of wells was re-used and was therefore less efficient 
in the second experiment. Thus always fresh IgG should be used for coating.  
In conclusion, these functional assays suggest that promoting cellular senescence could be 
beneficial for the clearance of non-senescent cells in tumours and may result in a reduction 
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of the tumour. It still remains to be investigated how mouse models with neuroblastoma 
tumours and beyond that, patients respond to treatment with low dose HU or CPT. 
 
The importance of senescence, a stress response blocking the proliferation of the cell, is 
increasingly recognized. Transformation of pre-malignant cells to tumours requires evading 
senescence. Surprisingly, many malignant tumour cells are still able to senesce either 
spontaneously or in response to stress stimuli from outside. Senescent cells are not only 
affecting themselves, rather they influence their microenvironment and their neighbouring 
cells through secretory and cell bound factors. Senescence seems to have specific 
physiological functions (e.g. aging) and pathological consequences (e.g. tumour 
suppression). Importantly, immune cells can clear senescent tumour cells and hence induce 
tumour regression. Furthermore chemotherapeutic drugs have been shown to lead to cellular 
senescence which may be a reason for the therapeutic success. Moreover, studies suggest 
that therapeutics which target molecules required for tumour growth may lead to induction of 
senescence and tumour regression [196]. These points make senescence inducing 
therapeutics a promising option in the fight against cancer. The challenge is to translate 
these concepts into clinical oncology.  
 
With respect to our study, the future experiments should analyse CPT- and HU-treatment in 
vivo, e.g. to clarify whether low dose treatment in xeno-transplanted mice leads to reduced 
neuroblastic tumour growth. If successful, one of these drugs could be included into a clinical 
trial protocol in high-risk NB-patients. Future research in the field of molecular mechanisms of 
senescence and in particular induction of cellular senescence in neuroblastoma cells will 
hopefully contribute to improve treatment of high-risk NB-patients and thereby their survival 
rate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
74 
 
References 
1. Gurney, J.G., et al., Infant cancer in the U.S.: histology-specific incidence and 
trends, 1973 to 1992. Journal of pediatric hematology/oncology, 1997. 19(5): p. 
428-32. 
2. Brodeur, G.M., Neuroblastoma. Principles and Practice of Pediatric Oncology, 
2001: p. 895-937. 
3. Pearson, A., Pinkerton, R., Neuroblastoma. Paediatric oncology, 2004: p. 386-
415. 
4. Alexander, F., Neuroblastoma. The Urologic clinics of North America, 2000. 
27(3): p. 383-92, vii. 
5. Brodeur, G.M., Neuroblastoma: biological insights into a clinical enigma. Nature 
reviews. Cancer, 2003. 3(3): p. 203-16. 
6. Carachi, R., Perspectives on neuroblastoma. Pediatric surgery international, 2002. 
18(5-6): p. 299-305. 
7. Ambros, I.M., et al., Role of ploidy, chromosome 1p, and Schwann cells in the 
maturation of neuroblastoma. The New England journal of medicine, 1996. 
334(23): p. 1505-11. 
8. Maris, J.M. and K.K. Matthay, Molecular biology of neuroblastoma. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology, 
1999. 17(7): p. 2264-79. 
9. Lastowska, M., et al., Comprehensive genetic and histopathologic study reveals 
three types of neuroblastoma tumors. Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology, 2001. 19(12): p. 3080-90. 
10. Look, A.T., et al., Clinical relevance of tumor cell ploidy and N-myc gene 
amplification in childhood neuroblastoma: a Pediatric Oncology Group study. 
Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology, 1991. 9(4): p. 581-91. 
11. Kaneko, Y., et al., Different karyotypic patterns in early and advanced stage 
neuroblastomas. Cancer research, 1987. 47(1): p. 311-8. 
12. Ambros, P.F., et al., Regression and progression in neuroblastoma. Does genetics 
predict tumour behaviour? European journal of cancer, 1995. 31A(4): p. 510-5. 
13. Maris, J.M., et al., Significance of chromosome 1p loss of heterozygosity in 
neuroblastoma. Cancer research, 1995. 55(20): p. 4664-9. 
14. Caron, H., et al., Allelic loss of chromosome 1p as a predictor of unfavorable 
outcome in patients with neuroblastoma. The New England journal of medicine, 
1996. 334(4): p. 225-30. 
15. Attiyeh, E.F., et al., Chromosome 1p and 11q deletions and outcome in 
neuroblastoma. The New England journal of medicine, 2005. 353(21): p. 2243-
53. 
16. Fong, C.T., et al., Loss of heterozygosity for the short arm of chromosome 1 in 
human neuroblastomas: correlation with N-myc amplification. Proceedings of the 
National Academy of Sciences of the United States of America, 1989. 86(10): p. 
3753-7. 
17. Caron, H., Allelic loss of chromosome 1 and additional chromosome 17 material 
are both unfavourable prognostic markers in neuroblastoma. Medical and 
pediatric oncology, 1995. 24(4): p. 215-21. 
 
75 
 
18. Bown, N., et al., Gain of chromosome arm 17q and adverse outcome in patients 
with neuroblastoma. The New England journal of medicine, 1999. 340(25): p. 
1954-61. 
19. Spitz, R., et al., Gain of distal chromosome arm 17q is not associated with poor 
prognosis in neuroblastoma. Clinical cancer research : an official journal of the 
American Association for Cancer Research, 2003. 9(13): p. 4835-40. 
20. Brodeur, G.M., et al., Amplification of N-myc in untreated human neuroblastomas 
correlates with advanced disease stage. Science, 1984. 224(4653): p. 1121-4. 
21. Seeger, R.C., et al., Association of multiple copies of the N-myc oncogene with 
rapid progression of neuroblastomas. The New England journal of medicine, 
1985. 313(18): p. 1111-6. 
22. Caron, H., et al., Allelic loss of the short arm of chromosome 4 in neuroblastoma 
suggests a novel tumour suppressor gene locus. Human genetics, 1996. 97(6): p. 
834-7. 
23. Thompson, P.M., et al., Homozygous deletion of CDKN2A (p16INK4a/p14ARF) 
but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer 
research, 2001. 61(2): p. 679-86. 
24. Schleiermacher, G., et al., Chromosomal CGH identifies patients with a higher 
risk of relapse in neuroblastoma without MYCN amplification. British journal of 
cancer, 2007. 97(2): p. 238-46. 
25. Brodeur, G.M., et al., Revisions of the international criteria for neuroblastoma 
diagnosis, staging, and response to treatment. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology, 1993. 11(8): p. 
1466-77. 
26. Haase, G.M., C. Perez, and J.B. Atkinson, Current aspects of biology, risk 
assessment, and treatment of neuroblastoma. Seminars in surgical oncology, 
1999. 16(2): p. 91-104. 
27. Park, J.R., A. Eggert, and H. Caron, Neuroblastoma: biology, prognosis, and 
treatment. Pediatric clinics of North America, 2008. 55(1): p. 97-120, x. 
28. Modak, S. and N.K. Cheung, Neuroblastoma: Therapeutic strategies for a clinical 
enigma. Cancer treatment reviews, 2010. 36(4): p. 307-17. 
29. Johnson, E., S.M. Dean, and P.M. Sondel, Antibody-based immunotherapy in 
high-risk neuroblastoma. Expert reviews in molecular medicine, 2007. 9(34): p. 1-
21. 
30. Castel, V., V. Segura, and A. Canete, Treatment of high-risk neuroblastoma with 
anti-GD2 antibodies. Clinical & translational oncology : official publication of the 
Federation of Spanish Oncology Societies and of the National Cancer Institute of 
Mexico, 2010. 12(12): p. 788-93. 
31. Schwab, M., et al., Amplified DNA with limited homology to myc cellular 
oncogene is shared by human neuroblastoma cell lines and a neuroblastoma 
tumour. Nature, 1983. 305(5931): p. 245-8. 
32. Kohl, N.E., et al., Transposition and amplification of oncogene-related sequences 
in human neuroblastomas. Cell, 1983. 35(2 Pt 1): p. 359-67. 
33. Schwab, M., et al., Chromosome localization in normal human cells and 
neuroblastomas of a gene related to c-myc. Nature, 1984. 308(5956): p. 288-91. 
34. Corvi, R., et al., MYCN is retained in single copy at chromosome 2 band p23-24 
during amplification in human neuroblastoma cells. Proceedings of the National 
Academy of Sciences of the United States of America, 1994. 91(12): p. 5523-7. 
35. Brodeur, G.M. and C.T. Fong, Molecular biology and genetics of human 
neuroblastoma. Cancer genetics and cytogenetics, 1989. 41(2): p. 153-74. 
 
76 
 
36. Reiter, J.L. and G.M. Brodeur, MYCN is the only highly expressed gene from the 
core amplified domain in human neuroblastomas. Genes, chromosomes & cancer, 
1998. 23(2): p. 134-40. 
37. Scott, D., et al., Genes co-amplified with MYCN in neuroblastoma: silent 
passengers or co-determinants of phenotype? Cancer letters, 2003. 197(1-2): p. 
81-6. 
38. De Preter, K., et al., Quantification of MYCN, DDX1, and NAG gene copy number 
in neuroblastoma using a real-time quantitative PCR assay. Modern pathology : 
an official journal of the United States and Canadian Academy of Pathology, Inc, 
2002. 15(2): p. 159-66. 
39. Lee, W.H., A.L. Murphree, and W.F. Benedict, Expression and amplification of 
the N-myc gene in primary retinoblastoma. Nature, 1984. 309(5967): p. 458-60. 
40. Nisen, P.D., et al., Enhanced expression of the N-myc gene in Wilms' tumors. 
Cancer research, 1986. 46(12 Pt 1): p. 6217-22. 
41. Rouah, E., et al., N-myc amplification and neuronal differentiation in human 
primitive neuroectodermal tumors of the central nervous system. Cancer research, 
1989. 49(7): p. 1797-801. 
42. Seeger, R.C., et al., Expression of N-myc by neuroblastomas with one or multiple 
copies of the oncogene. Progress in clinical and biological research, 1988. 271: p. 
41-9. 
43. Wenzel, A. and M. Schwab, The mycN/max protein complex in neuroblastoma. 
Short review. European journal of cancer, 1995. 31A(4): p. 516-9. 
44. Dang, C.V., et al., The c-Myc target gene network. Seminars in cancer biology, 
2006. 16(4): p. 253-64. 
45. Hirvonen, H., et al., Expression of the myc proto-oncogenes in developing human 
fetal brain. Oncogene, 1990. 5(12): p. 1787-97. 
46. Zimmerman, K.A., et al., Differential expression of myc family genes during 
murine development. Nature, 1986. 319(6056): p. 780-3. 
47. Grady, E.F., M. Schwab, and W. Rosenau, Expression of N-myc and c-src during 
the development of fetal human brain. Cancer research, 1987. 47(11): p. 2931-6. 
48. Hirning, U., et al., A comparative analysis of N-myc and c-myc expression and 
cellular proliferation in mouse organogenesis. Mechanisms of development, 
1991. 33(2): p. 119-25. 
49. Stanton, B.R., et al., Loss of N-myc function results in embryonic lethality and 
failure of the epithelial component of the embryo to develop. Genes & 
development, 1992. 6(12A): p. 2235-47. 
50. Malynn, B.A., et al., N-myc can functionally replace c-myc in murine 
development, cellular growth, and differentiation. Genes & development, 2000. 
14(11): p. 1390-9. 
51. Alam, G., et al., MYCN promotes the expansion of Phox2B-positive neuronal 
progenitors to drive neuroblastoma development. The American journal of 
pathology, 2009. 175(2): p. 856-66. 
52. Hayflick, L. and P.S. Moorhead, The serial cultivation of human diploid cell 
strains. Experimental cell research, 1961. 25: p. 585-621. 
53. Sherwood, S.W., et al., Defining cellular senescence in IMR-90 cells: a flow 
cytometric analysis. Proceedings of the National Academy of Sciences of the 
United States of America, 1988. 85(23): p. 9086-90. 
54. Vojta, P.J. and J.C. Barrett, Genetic analysis of cellular senescence. Biochimica et 
biophysica acta, 1995. 1242(1): p. 29-41. 
 
77 
 
55. Cristofalo, V.J., et al., Alterations in the responsiveness of senescent cells to 
growth factors. Journal of gerontology, 1989. 44(6): p. 55-62. 
56. Goldstein, S., Replicative senescence: the human fibroblast comes of age. 
Science, 1990. 249(4973): p. 1129-33. 
57. Matsumura, T., Z. Zerrudo, and L. Hayflick, Senescent human diploid cells in 
culture: survival, DNA synthesis and morphology. Journal of gerontology, 1979. 
34(3): p. 328-34. 
58. Hampel, B., et al., Differential regulation of apoptotic cell death in senescent 
human cells. Experimental gerontology, 2004. 39(11-12): p. 1713-21. 
59. Marcotte, R., C. Lacelle, and E. Wang, Senescent fibroblasts resist apoptosis by 
downregulating caspase-3. Mechanisms of ageing and development, 2004. 
125(10-11): p. 777-83. 
60. Jackson, J.G. and O.M. Pereira-Smith, p53 is preferentially recruited to the 
promoters of growth arrest genes p21 and GADD45 during replicative senescence 
of normal human fibroblasts. Cancer research, 2006. 66(17): p. 8356-60. 
61. Dimri, G.P., et al., A biomarker that identifies senescent human cells in culture 
and in aging skin in vivo. Proceedings of the National Academy of Sciences of the 
United States of America, 1995. 92(20): p. 9363-7. 
62. Lee, B.Y., et al., Senescence-associated beta-galactosidase is lysosomal beta-
galactosidase. Aging cell, 2006. 5(2): p. 187-95. 
63. Zhang, H., K.H. Pan, and S.N. Cohen, Senescence-specific gene expression 
fingerprints reveal cell-type-dependent physical clustering of up-regulated 
chromosomal loci. Proceedings of the National Academy of Sciences of the 
United States of America, 2003. 100(6): p. 3251-6. 
64. Kuilman, T. and D.S. Peeper, Senescence-messaging secretome: SMS-ing cellular 
stress. Nature reviews. Cancer, 2009. 9(2): p. 81-94. 
65. Coppe, J.P., et al., Senescence-associated secretory phenotypes reveal cell-
nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS 
biology, 2008. 6(12): p. 2853-68. 
66. Coppe, J.P., et al., The senescence-associated secretory phenotype: the dark side 
of tumor suppression. Annual review of pathology, 2010. 5: p. 99-118. 
67. Narita, M., et al., Rb-mediated heterochromatin formation and silencing of E2F 
target genes during cellular senescence. Cell, 2003. 113(6): p. 703-16. 
68. Narita, M., et al., A novel role for high-mobility group a proteins in cellular 
senescence and heterochromatin formation. Cell, 2006. 126(3): p. 503-14. 
69. Zhang, R., et al., Formation of MacroH2A-containing senescence-associated 
heterochromatin foci and senescence driven by ASF1a and HIRA. Developmental 
cell, 2005. 8(1): p. 19-30. 
70. Di Micco, R., et al., Interplay between oncogene-induced DNA damage response 
and heterochromatin in senescence and cancer. Nature cell biology, 2011. 13(3): 
p. 292-302. 
71. Collado, M., M.A. Blasco, and M. Serrano, Cellular senescence in cancer and 
aging. Cell, 2007. 130(2): p. 223-33. 
72. Campisi, J., Cellular senescence as a tumor-suppressor mechanism. Trends in cell 
biology, 2001. 11(11): p. S27-31. 
73. Vijg, J. and J. Campisi, Puzzles, promises and a cure for ageing. Nature, 2008. 
454(7208): p. 1065-71. 
74. Freund, A., C.K. Patil, and J. Campisi, p38MAPK is a novel DNA damage 
response-independent regulator of the senescence-associated secretory 
phenotype. The EMBO journal, 2011. 30(8): p. 1536-48. 
 
78 
 
75. Chan, S.W., et al., Altering telomere structure allows telomerase to act in yeast 
lacking ATM kinases. Current biology : CB, 2001. 11(16): p. 1240-50. 
76. de Lange, T., Shelterin: the protein complex that shapes and safeguards human 
telomeres. Genes & development, 2005. 19(18): p. 2100-10. 
77. Blasco, M.A., Telomeres and human disease: ageing, cancer and beyond. Nature 
reviews. Genetics, 2005. 6(8): p. 611-22. 
78. von Zglinicki, T., et al., Human cell senescence as a DNA damage response. 
Mechanisms of ageing and development, 2005. 126(1): p. 111-7. 
79. Harley, C.B., A.B. Futcher, and C.W. Greider, Telomeres shorten during ageing 
of human fibroblasts. Nature, 1990. 345(6274): p. 458-60. 
80. Stewart, S.A. and R.A. Weinberg, Telomeres: cancer to human aging. Annual 
review of cell and developmental biology, 2006. 22: p. 531-57. 
81. Muntoni, A. and R.R. Reddel, The first molecular details of ALT in human tumor 
cells. Human molecular genetics, 2005. 14 Spec No. 2: p. R191-6. 
82. Bodnar, A.G., et al., Extension of life-span by introduction of telomerase into 
normal human cells. Science, 1998. 279(5349): p. 349-52. 
83. Robles, S.J. and G.R. Adami, Agents that cause DNA double strand breaks lead to 
p16INK4a enrichment and the premature senescence of normal fibroblasts. 
Oncogene, 1998. 16(9): p. 1113-23. 
84. Di Leonardo, A., et al., DNA damage triggers a prolonged p53-dependent G1 
arrest and long-term induction of Cip1 in normal human fibroblasts. Genes & 
development, 1994. 8(21): p. 2540-51. 
85. Chen, Q. and B.N. Ames, Senescence-like growth arrest induced by hydrogen 
peroxide in human diploid fibroblast F65 cells. Proceedings of the National 
Academy of Sciences of the United States of America, 1994. 91(10): p. 4130-4. 
86. Finkel, T. and N.J. Holbrook, Oxidants, oxidative stress and the biology of ageing. 
Nature, 2000. 408(6809): p. 239-47. 
87. Wahl, G.M. and A.M. Carr, The evolution of diverse biological responses to DNA 
damage: insights from yeast and p53. Nature cell biology, 2001. 3(12): p. E277-
86. 
88. Han, Z., et al., Role of p21 in apoptosis and senescence of human colon cancer 
cells treated with camptothecin. The Journal of biological chemistry, 2002. 
277(19): p. 17154-60. 
89. Shay, J.W. and I.B. Roninson, Hallmarks of senescence in carcinogenesis and 
cancer therapy. Oncogene, 2004. 23(16): p. 2919-33. 
90. Park, J.I., et al., Hydroxyurea induces a senescence-like change of K562 human 
erythroleukemia cell. Journal of cancer research and clinical oncology, 2000. 
126(8): p. 455-60. 
91. Chang, B.D., et al., A senescence-like phenotype distinguishes tumor cells that 
undergo terminal proliferation arrest after exposure to anticancer agents. Cancer 
research, 1999. 59(15): p. 3761-7. 
92. Sherr, C.J. and R.A. DePinho, Cellular senescence: mitotic clock or culture 
shock? Cell, 2000. 102(4): p. 407-10. 
93. Lu, T. and T. Finkel, Free radicals and senescence. Experimental cell research, 
2008. 314(9): p. 1918-22. 
94. Wei, S. and J.M. Sedivy, Expression of catalytically active telomerase does not 
prevent premature senescence caused by overexpression of oncogenic Ha-Ras in 
normal human fibroblasts. Cancer research, 1999. 59(7): p. 1539-43. 
95. Serrano, M., et al., Oncogenic ras provokes premature cell senescence associated 
with accumulation of p53 and p16INK4a. Cell, 1997. 88(5): p. 593-602. 
 
79 
 
96. Kuilman, T., et al., The essence of senescence. Genes & development, 2010. 
24(22): p. 2463-79. 
97. Wu, C.H., et al., Cellular senescence is an important mechanism of tumor 
regression upon c-Myc inactivation. Proceedings of the National Academy of 
Sciences of the United States of America, 2007. 104(32): p. 13028-33. 
98. Hydbring, P., et al., Phosphorylation by Cdk2 is required for Myc to repress Ras-
induced senescence in cotransformation. Proceedings of the National Academy of 
Sciences of the United States of America, 2010. 107(1): p. 58-63. 
99. Chen, Z., et al., Crucial role of p53-dependent cellular senescence in suppression 
of Pten-deficient tumorigenesis. Nature, 2005. 436(7051): p. 725-30. 
100. Courtois-Cox, S., et al., A negative feedback signaling network underlies 
oncogene-induced senescence. Cancer cell, 2006. 10(6): p. 459-72. 
101. Ben-Porath, I. and R.A. Weinberg, The signals and pathways activating cellular 
senescence. The international journal of biochemistry & cell biology, 2005. 37(5): 
p. 961-76. 
102. Vandenberk, B., et al., p16INK4a: A central player in cellular senescence and a 
promising aging biomarker in elderly cancer patients. 2011. 2(4): p. 259-269. 
103. Canepa, E.T., et al., INK4 proteins, a family of mammalian CDK inhibitors with 
novel biological functions. IUBMB life, 2007. 59(7): p. 419-26. 
104. Ciccia, A. and S.J. Elledge, The DNA damage response: making it safe to play 
with knives. Molecular cell, 2010. 40(2): p. 179-204. 
105. Campisi, J., Suppressing cancer: the importance of being senescent. Science, 
2005. 309(5736): p. 886-7. 
106. Bringold, F. and M. Serrano, Tumor suppressors and oncogenes in cellular 
senescence. Experimental gerontology, 2000. 35(3): p. 317-29. 
107. Li, D.M. and H. Sun, PTEN/MMAC1/TEP1 suppresses the tumorigenicity and 
induces G1 cell cycle arrest in human glioblastoma cells. Proceedings of the 
National Academy of Sciences of the United States of America, 1998. 95(26): p. 
15406-11. 
108. Tresini, M., et al., A phosphatidylinositol 3-kinase inhibitor induces a senescent-
like growth arrest in human diploid fibroblasts. Cancer research, 1998. 58(1): p. 
1-4. 
109. Lloyd, R.V., et al., p27kip1: a multifunctional cyclin-dependent kinase inhibitor 
with prognostic significance in human cancers. The American journal of 
pathology, 1999. 154(2): p. 313-23. 
110. Collado, M. and M. Serrano, Senescence in tumours: evidence from mice and 
humans. Nature reviews. Cancer, 2010. 10(1): p. 51-7. 
111. Adams, P.D., Healing and hurting: molecular mechanisms, functions, and 
pathologies of cellular senescence. Molecular cell, 2009. 36(1): p. 2-14. 
112. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 
57-70. 
113. Kim, W.Y. and N.E. Sharpless, The regulation of INK4/ARF in cancer and aging. 
Cell, 2006. 127(2): p. 265-75. 
114. Campisi, J., Senescent cells, tumor suppression, and organismal aging: good 
citizens, bad neighbors. Cell, 2005. 120(4): p. 513-22. 
115. Morton, J.P., et al., Mutant p53 drives metastasis and overcomes growth 
arrest/senescence in pancreatic cancer. Proceedings of the National Academy of 
Sciences of the United States of America, 2010. 107(1): p. 246-51. 
 
80 
 
116. Ha, L., et al., ARF functions as a melanoma tumor suppressor by inducing p53-
independent senescence. Proceedings of the National Academy of Sciences of the 
United States of America, 2007. 104(26): p. 10968-73. 
117. Herbig, U., et al., Cellular senescence in aging primates. Science, 2006. 
311(5765): p. 1257. 
118. Minamino, T. and I. Komuro, Vascular cell senescence: contribution to 
atherosclerosis. Circulation research, 2007. 100(1): p. 15-26. 
119. Price, J.S., et al., The role of chondrocyte senescence in osteoarthritis. Aging cell, 
2002. 1(1): p. 57-65. 
120. Wiemann, S.U., et al., Hepatocyte telomere shortening and senescence are 
general markers of human liver cirrhosis. FASEB journal : official publication of 
the Federation of American Societies for Experimental Biology, 2002. 16(9): p. 
935-42. 
121. Roninson, I.B., Tumor senescence as a determinant of drug response in vivo. 
Drug resistance updates : reviews and commentaries in antimicrobial and 
anticancer chemotherapy, 2002. 5(5): p. 204-8. 
122. te Poele, R.H., et al., DNA damage is able to induce senescence in tumor cells in 
vitro and in vivo. Cancer research, 2002. 62(6): p. 1876-83. 
123. Roberson, R.S., et al., Escape from therapy-induced accelerated cellular 
senescence in p53-null lung cancer cells and in human lung cancers. Cancer 
research, 2005. 65(7): p. 2795-803. 
124. Roninson, I.B., Tumor cell senescence in cancer treatment. Cancer research, 
2003. 63(11): p. 2705-15. 
125. Narath, R., et al., Induction of senescence in MYCN amplified neuroblastoma cell 
lines by hydroxyurea. Genes Chromosomes Cancer, 2007. 46(2): p. 130-42. 
126. Ambros, I.M., et al., Neuroblastoma cells can actively eliminate supernumerary 
MYCN gene copies by micronucleus formation--sign of tumour cell revertance? 
European journal of cancer, 1997. 33(12): p. 2043-9. 
127. Tumilowicz, J.J., et al., Definition of a continuous human cell line derived from 
neuroblastoma. Cancer research, 1970. 30(8): p. 2110-8. 
128. Biedler, J.L., L. Helson, and B.A. Spengler, Morphology and growth, 
tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous 
culture. Cancer research, 1973. 33(11): p. 2643-52. 
129. Canute, G.W., et al., Hydroxyurea accelerates the loss of epidermal growth factor 
receptor genes amplified as double-minute chromosomes in human glioblastoma 
multiforme. Neurosurgery, 1996. 39(5): p. 976-83. 
130. Snapka, R.M. and A. Varshavsky, Loss of unstably amplified dihydrofolate 
reductase genes from mouse cells is greatly accelerated by hydroxyurea. 
Proceedings of the National Academy of Sciences of the United States of 
America, 1983. 80(24): p. 7533-7. 
131. Schulz, G., et al., Detection of ganglioside GD2 in tumor tissues and sera of 
neuroblastoma patients. Cancer research, 1984. 44(12 Pt 1): p. 5914-20. 
132. Svennerholm, L., et al., Gangliosides and allied glycosphingolipids in human 
peripheral nerve and spinal cord. Biochimica et biophysica acta, 1994. 1214(2): 
p. 115-23. 
133. Ponta, H., L. Sherman, and P.A. Herrlich, CD44: from adhesion molecules to 
signalling regulators. Nature reviews. Molecular cell biology, 2003. 4(1): p. 33-
45. 
 
81 
 
134. Fichter, M., et al., Expression of CD44 isoforms in neuroblastoma cells is 
regulated by PI 3-kinase and protein kinase C. Oncogene, 1997. 14(23): p. 2817-
24. 
135. Liu, J. and G. Jiang, CD44 and hematologic malignancies. Cellular & molecular 
immunology, 2006. 3(5): p. 359-65. 
136. Ponti, D., et al., Isolation and in vitro propagation of tumorigenic breast cancer 
cells with stem/progenitor cell properties. Cancer research, 2005. 65(13): p. 5506-
11. 
137. Shmelkov, S.V., et al., CD133 expression is not restricted to stem cells, and both 
CD133+ and CD133- metastatic colon cancer cells initiate tumors. The Journal 
of clinical investigation, 2008. 118(6): p. 2111-20. 
138. Gross, N., et al., CD44H expression by human neuroblastoma cells: relation to 
MYCN amplification and lineage differentiation. Cancer research, 1994. 54(15): p. 
4238-42. 
139. Gross, N., K. Balmas, and C.B. Brognara, Absence of functional CD44 
hyaluronan receptor on human NMYC-amplified neuroblastoma cells. Cancer 
research, 1997. 57(7): p. 1387-93. 
140. Wolfl, M., et al., Expression of MHC class I, MHC class II, and cancer germline 
antigens in neuroblastoma. Cancer immunology, immunotherapy : CII, 2005. 
54(4): p. 400-6. 
141. Prigione, I., et al., Immunogenicity of human neuroblastoma. Annals of the New 
York Academy of Sciences, 2004. 1028: p. 69-80. 
142. Hicklin, D.J., F.M. Marincola, and S. Ferrone, HLA class I antigen 
downregulation in human cancers: T-cell immunotherapy revives an old story. 
Molecular medicine today, 1999. 5(4): p. 178-86. 
143. Corrias, M.V., et al., Lack of HLA-class I antigens in human neuroblastoma cells: 
analysis of its relationship to TAP and tapasin expression. Tissue antigens, 2001. 
57(2): p. 110-7. 
144. Lampson, L.A., C.A. Fisher, and J.P. Whelan, Striking paucity of HLA-A, B, C 
and beta 2-microglobulin on human neuroblastoma cell lines. Journal of 
immunology, 1983. 130(5): p. 2471-8. 
145. Raffaghello, L., et al., Multiple defects of the antigen-processing machinery 
components in human neuroblastoma: immunotherapeutic implications. 
Oncogene, 2005. 24(29): p. 4634-44. 
146. Coughlin, C.M., et al., Immunosurveillance and survivin-specific T-cell immunity 
in children with high-risk neuroblastoma. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology, 2006. 24(36): p. 5725-34. 
147. Heitger, A. and S. Ladisch, Gangliosides block antigen presentation by human 
monocytes. Biochimica et biophysica acta, 1996. 1303(2): p. 161-8. 
148. Jensen, C., et al., Complexity of the influence of gangliosides on histamine release 
from human basophils and rat mast cells. Agents and actions, 1987. 21(1-2): p. 
79-82. 
149. Ladisch, S., H. Becker, and L. Ulsh, Immunosuppression by human gangliosides: 
I. Relationship of carbohydrate structure to the inhibition of T cell responses. 
Biochimica et biophysica acta, 1992. 1125(2): p. 180-8. 
150. Ladisch, S., et al., Modulation of the immune response by gangliosides. Inhibition 
of adherent monocyte accessory function in vitro. The Journal of clinical 
investigation, 1984. 74(6): p. 2074-81. 
 
82 
 
151. Miller, H.C. and W.J. Esselman, Modulation of the immune response by antigen-
reactive lymphocytes after cultivation with gangliosides. Journal of immunology, 
1975. 115(3): p. 839-43. 
152. Shen, W., et al., Modulation of CD4 Th cell differentiation by ganglioside GD1a 
in vitro. Journal of immunology, 2005. 175(8): p. 4927-34. 
153. Shen, W., et al., Inhibition of TLR activation and up-regulation of IL-1R-
associated kinase-M expression by exogenous gangliosides. Journal of 
immunology, 2008. 180(7): p. 4425-32. 
154. Whisler, R.L. and A.J. Yates, Regulation of lymphocyte responses by human 
gangliosides. I. Characteristics of inhibitory effects and the induction of impaired 
activation. Journal of immunology, 1980. 125(5): p. 2106-11. 
155. Li, R.X. and S. Ladisch, Shedding of human neuroblastoma gangliosides. 
Biochimica et biophysica acta, 1991. 1083(1): p. 57-64. 
156. Rivoltini, L., et al., Phenotypic and functional analysis of lymphocytes infiltrating 
paediatric tumours, with a characterization of the tumour phenotype. Cancer 
immunology, immunotherapy : CII, 1992. 34(4): p. 241-51. 
157. Airoldi, I., et al., Expression of costimulatory molecules in human neuroblastoma. 
Evidence that CD40+ neuroblastoma cells undergo apoptosis following 
interaction with CD40L. British journal of cancer, 2003. 88(10): p. 1527-36. 
158. Main, E.K., et al., Human neuroblastoma cell lines are susceptible to lysis by 
natural killer cells but not by cytotoxic T lymphocytes. Journal of immunology, 
1985. 135(1): p. 242-6. 
159. Rossi, A.R., et al., Lysis of neuroblastoma cell lines by human natural killer cells 
activated by interleukin-2 and interleukin-12. Blood, 1994. 83(5): p. 1323-8. 
160. Metelitsa, L.S., et al., Human NKT cells mediate antitumor cytotoxicity directly by 
recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to 
activate NK cells. Journal of immunology, 2001. 167(6): p. 3114-22. 
161. Seeger, R.C., Immunology and immunotherapy of neuroblastoma. Seminars in 
cancer biology, 2011. 21(4): p. 229-37. 
162. Raffaghello, L. and V. Pistoia, Immunotherapy of neuroblastoma: present, past 
and future. Expert review of neurotherapeutics, 2006. 6(4): p. 509-18. 
163. Tonini, G.P. and V. Pistoia, Molecularly guided therapy of neuroblastoma: a 
review of different approaches. Current pharmaceutical design, 2006. 12(18): p. 
2303-17. 
164. Yu, A.L., et al., Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin 
for neuroblastoma. The New England journal of medicine, 2010. 363(14): p. 
1324-34. 
165. Rakhra, K., et al., CD4(+) T cells contribute to the remodeling of the 
microenvironment required for sustained tumor regression upon oncogene 
inactivation. Cancer cell, 2010. 18(5): p. 485-98. 
166. Reimann, M., C.A. Schmitt, and S. Lee, Non-cell-autonomous tumor suppression: 
oncogene-provoked apoptosis promotes tumor cell senescence via stromal 
crosstalk. Journal of molecular medicine, 2011. 89(9): p. 869-75. 
167. Kang, T.W., et al., Senescence surveillance of pre-malignant hepatocytes limits 
liver cancer development. Nature, 2011. 479(7374): p. 547-51. 
168. Carson, J.P., et al., Pharmacogenomic identification of targets for adjuvant 
therapy with the topoisomerase poison camptothecin. Cancer research, 2004. 
64(6): p. 2096-104. 
169. Djordjevic, B. and W. Szybalski, Genetics of human cell lines. III. Incorporation 
of 5-bromo- and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells 
 
83 
 
and its effect on radiation sensitivity. The Journal of experimental medicine, 1960. 
112: p. 509-31. 
170. Michishita, E., et al., 5-Bromodeoxyuridine induces senescence-like phenomena in 
mammalian cells regardless of cell type or species. Journal of biochemistry, 1999. 
126(6): p. 1052-9. 
171. Minagawa, S., et al., Early BrdU-responsive genes constitute a novel class of 
senescence-associated genes in human cells. Experimental cell research, 2005. 
304(2): p. 552-8. 
172. Acosta, S., et al., Comprehensive characterization of neuroblastoma cell line 
subtypes reveals bilineage potential similar to neural crest stem cells. BMC 
developmental biology, 2009. 9: p. 12. 
173. Miller, J., ed. Experiments in molecular genetics. Cold Spring Harbor Laboratory, 
Cold Spring Harbor, New York.1972. 
174. Ambros, P.F., et al., International consensus for neuroblastoma molecular 
diagnostics: report from the International Neuroblastoma Risk Group (INRG) 
Biology Committee. British journal of cancer, 2009. 100(9): p. 1471-82. 
175. Terman, A. and U.T. Brunk, Lipofuscin: mechanisms of formation and increase 
with age. APMIS : acta pathologica, microbiologica, et immunologica 
Scandinavica, 1998. 106(2): p. 265-76. 
176. Debacq-Chainiaux, F., et al., Protocols to detect senescence-associated beta-
galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and 
in vivo. Nature protocols, 2009. 4(12): p. 1798-806. 
177. Bordow, S.B., et al., Prognostic significance of MYCN oncogene expression in 
childhood neuroblastoma. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology, 1998. 16(10): p. 3286-94. 
178. Tang, X.X., et al., The MYCN enigma: significance of MYCN expression in 
neuroblastoma. Cancer research, 2006. 66(5): p. 2826-33. 
179. Balajee, A.S. and C.R. Geard, Replication protein A and gamma-H2AX foci 
assembly is triggered by cellular response to DNA double-strand breaks. 
Experimental cell research, 2004. 300(2): p. 320-34. 
180. Sottile, F., et al., A chemical screen identifies the chemotherapeutic drug 
topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. 
Oncotarget, 2012. 3(5): p. 535-45. 
181. Levkoff, L.H., et al., Bromodeoxyuridine inhibits cancer cell proliferation in vitro 
and in vivo. Neoplasia, 2008. 10(8): p. 804-16. 
182. Taupin, P., BrdU immunohistochemistry for studying adult neurogenesis: 
paradigms, pitfalls, limitations, and validation. Brain research reviews, 2007. 
53(1): p. 198-214. 
183. Khanna, R., Tumour surveillance: missing peptides and MHC molecules. 
Immunology and cell biology, 1998. 76(1): p. 20-6. 
184. Zindy, F., et al., Myc signaling via the ARF tumor suppressor regulates p53-
dependent apoptosis and immortalization. Genes & development, 1998. 12(15): p. 
2424-33. 
185. Hydbring, P. and L.G. Larsson, Cdk2: a key regulator of the senescence control 
function of Myc. Aging, 2010. 2(4): p. 244-50. 
186. Molenaar, J.J., et al., Inactivation of CDK2 is synthetically lethal to MYCN over-
expressing cancer cells. Proceedings of the National Academy of Sciences of the 
United States of America, 2009. 106(31): p. 12968-73. 
 
84 
 
187. Morandi, E., et al., Gene expression time-series analysis of camptothecin effects in 
U87-MG and DBTRG-05 glioblastoma cell lines. Molecular cancer, 2008. 7: p. 
66. 
188. Flatten, K., et al., The role of checkpoint kinase 1 in sensitivity to topoisomerase I 
poisons. The Journal of biological chemistry, 2005. 280(14): p. 14349-55. 
189. Huang, T.T., et al., NF-kappaB activation by camptothecin. A linkage between 
nuclear DNA damage and cytoplasmic signaling events. The Journal of biological 
chemistry, 2000. 275(13): p. 9501-9. 
190. Minderman, H., et al., In vitro and in vivo irinotecan-induced changes in 
expression profiles of cell cycle and apoptosis-associated genes in acute myeloid 
leukemia cells. Molecular cancer therapeutics, 2005. 4(6): p. 885-900. 
191. Masterson, J.C. and S. O'Dea, 5-Bromo-2-deoxyuridine activates DNA damage 
signalling responses and induces a senescence-like phenotype in p16-null lung 
cancer cells. Anti-cancer drugs, 2007. 18(9): p. 1053-68. 
192. Passos, J.F., et al., Feedback between p21 and reactive oxygen production is 
necessary for cell senescence. Molecular systems biology, 2010. 6: p. 347. 
193. Liu, D. and P.J. Hornsby, Senescent human fibroblasts increase the early growth 
of xenograft tumors via matrix metalloproteinase secretion. Cancer research, 
2007. 67(7): p. 3117-26. 
194. Nelson, G., et al., A senescent cell bystander effect: senescence-induced 
senescence. Aging cell, 2012. 11(2): p. 345-9. 
195. Floutsis, G., L. Ulsh, and S. Ladisch, Immunosuppressive activity of human 
neuroblastoma tumor gangliosides. International journal of cancer. Journal 
international du cancer, 1989. 43(1): p. 6-9. 
196. Kong, Y., et al., Regulation of senescence in cancer and aging. Journal of aging 
research, 2011. 2011: p. 963172. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
85 
 
List of abbreviations 
 
BrdU Bromodeoxyuridine  
BSA  Bovine Serum Albumin 
CD44  Phagocytic Glycoprotein-1 
CFSE Carboxyfluorescein Diacetate Succinimidyl Ester  
CM conditioned medium 
CPD Cell Proliferation Dye 
CPT Camptothecin 
CTL Cytotoxic T lymphocytes 
CTRL control 
DAPI  4'-6-Diamidino-2-phenylindole 
DDR  DNA damage response 
dmin  double minute chromosome 
DNA  deoxyribonucleic acid 
FACS fluorescence activated cell sorting 
F-cells  flat-cells 
FISH Fluorescence in situ hybridization 
FITC fluorescein isothiocyanate 
Fsp spontaneous F-cell 
GD2 GD2 ganglioside 
HEPES  (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid ) 
hsr  homogenously staining region 
HU Hyroxyurea 
IC50 The half maximal inhibitory concentration 
ind. induced 
MHC-1  major histocompatibility complex class 1 
MNA MYCN amplification 
MTT methylthiazolyldiphenyl-tetrazolium bromide 
MYCN  v-myc myelocytomatosis viral related oncogene, neuroblastoma derived 
NB  Neuroblastoma 
NB-Ma Neuroblastoma-Ma 
N-cells  neuronal cells 
PI propidium iodide 
RT room temperature 
SA-β-Gal  senescence-associated-β-galactosidase 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sp.F spontaneous F-cell 
STA-NB-10 St. Anna Neuroblastoma 10 
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